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ABSTRACT 
 
Altough microvascular surgery is routine nowadays, the problem of intra- or postoperative 
thrombosis still exists in under 5 % to 25 % of cases. The search for an ideal topical 
antithrombotic agent therefore goes on. The aims of the present study were threefold: first, to 
test sensitive new markers for coagulation and fibrinolysis during and after reconstructive 
microsurgery in humans to see if there was any association with failures. Second, the failed 
anastomoses were subjected to immunohistochemical analysis. Finally, a promising new 
topical antithrombotic agent, native heparin proteoglycan (HEP-PG), was experimentally 
tested in vivo in an anastomosis model in rats.  
 
Coagulation and fibrinolytic markers were analysed in 24 patients in three different groups: 
patients undergoing late breast reconstruction with a TRAM flap, patients with trauma or 
chronic ulcer in the lower extremities, and patients with cancer in the oral cavity or the 
extremities. The plasma markers analysed included fibrinogen, TAT, F1+2, D-dimer, tPA and 
PAI-1. When assessed during microsurgical tissue transfers, thrombin generation as measured 
by TAT and F1+2 associated with threatening flap failure and following reoperation. These 
markers could also be used for the postoperative follow-up and evaluation of patients in need 
of more intense antithrombotic therapy in order to avoid reoperations. Thrombin generation 
was already seen before the operation in half of the TRAM patients with intraoperative 
thrombosis, and at the time of thrombosis both thrombin generation and fibrinolysis activation 
were evident in patients with obvious intraoperative thrombosis. Moreover, distinct thrombin 
generation was observed at 24 h in one patient with subsequent edge necrosis. Patients with 
lower extremity trauma who were in a hypercoagulable state before the operation and who 
required reoperation showed consistent thrombin generation at the end of primary surgery, 
which in part reflected coagulation activation due to excessive intraoperative bleeding. 
Meticulous hemostasis during surgery might therefore help to diminish the need for 
reoperations. Four out of seven patients with active cancer showed a preoperative 
hypercoagulable state, and two of them also had a thrombotic event with consistent activation 
of coagulation and fibrinolysis.  
 
All patients had been given thrombosis prophylaxis with LMWH, dalteparin. The level of 
anti-factor Xa activity was assessed as the indicator of the efficacy of LMWH. The level of 
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anti-factor Xa was under the recommended limit of 0.3 U/ml in all of the patients who had 
received anticoagulation with LMWH, dalteparin, the previous evening, and even some of 
those who had received it a few hours before the operation. Preoperative recognition of the 
hypercoagulable state, especially in patients with recent trauma or active cancer, could 
facilitate the targeting of meticulous antithrombotic protection perioperatively in these 
patients. Thus, a question remaining for new studies is: could a better perioperative 
anticoagulation control with LMWH help to reduce the risk of thrombotic events?  
 
A total of 17 vessel samples were collected from 13 patients and subjected to 
histopathological and immunohistochemical analyses. Analysis of the failed anastomoses 
revealed that technical failures are rare. Immunohistochemical studies showed a lack of 
endothelial cells adjacent to the anastomosis site as recognised by absent PECAM-1 staining, 
and colocalised recruitment of platelets and fibrin. Of interest was the finding that PECAM-1 
staining was absent in the single adherent layers of platelets but was found positive in micro 
and larger thrombi. This suggests a difference in behaviour between thrombosis that retains 
mural and thrombosis that extends to the lumen. The secondary thrombi at reoperations 
showed clear inflammatory signs in vessels that could be associated with enhanced 
coagulation and formation of fibrin-rich thrombi. Refined surgical techniques are essential to 
minimise the anastomotic injury responsible for the local thrombotic response, but it should 
be borne in mind that nearly all compromised anastomoses can be saved by having them 
redone by an experienced microsurgical team. Enhanced antithrombotic treatment might also 
support this salvage. 
 
Finally, the antithrombotic effect of native macromolecular HEP-PG was tested in an 
anastomosis model in rat common femoral arteries both acute and long term. We show that 
topically applied native macromolecular HEP-PG (10 µg/ml) effectively inhibit thrombus 
formation in microvascular arterial anastomoses in rats. The platelet thrombi induced during 
this experimental microvascular surgery were minimal shortly (10 min) after the 
thrombogenic challenge and remained so in the long term (72 h), too. These findings were 
confirmed by SEM analysis and quantified with Indium 111-labelled platelets when compared 
with saline, whereas unfractionated heparin at a 100-fold higher concentration failed to 
markedly reduce the thrombotic response. The local antithrombotic effect of HEP-PG led to 
neither prolonged anastomotic bleeding nor a systemic influence on platelet counts or 
thrombin time. HEP-PG, by having a strongly retaining bond to extracellular matrix, seem to 
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have potential as a locally active antithrombotic agent in arterial circulation. This strategy is 
applicable to microvascular surgery and to arteriovenous shunts, which frequently tend to 
occlude in patients with renal failure needing permanent access to dialysis. 
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1. INTRODUCTION 
 
Free microvascular tissue transplantations have become routine in plastic surgery, with 
success rates ranging from 90 % to 99 % (Harashina 1988, Percival et al. 1989, Khouri 1992, 
Suominen and Asko-Seljavaara 1995, Nieminen et al. 1999). According to the above authors, 
re-exploration is needed in 6-25% of cases, the most common findings being either arterial 
thrombosis or bleeding. The anastomosis itself promotes platelet adhesion and aggregation at 
the needle holes and, in the event of severe vessel injury, a platelet thrombus will form 
(Acland 1973, Yu-dong et al. 1989). Partial, dynamic thrombosis at the site of anastomosis 
can seed microemboli downstream to the flap. These cause vasospasm mediated by platelet 
metabolites, which can lead to secondary thrombosis (Barker et al. 1992, Weinzweig and 
Gonzalez 1995). Kinking of vessels or compression due to haematoma, oedema or too tight 
closure may also lead to diminished flow and secondary thrombosis (Percival et al. 1989, 
Suominen and Asko-Seljavaara 1995, Rieck et al. 1995). In some cases, even the experienced 
microsurgeon may have to redo an anastomosis several times during the primary operation 
because of recurrent thrombosis without an obvious cause. This could reflect the procoagulant 
state of the patient and insufficient anticoagulation therapy. 
           
An increased risk of thromboembolic events threatens patients with recent trauma or 
operation, infection or malignancy, who are in a hypercoagulable state before surgery 
(Kudrjashov et al. 1969, Bennet and Towler 1985, Hoffman 1991, Falanga et al. 1993). Many 
patients undergoing free flap transfer belong to this group. In addition, the surgery itself with 
subsequent bleeding activates the coagulation and fibrinolytic systems not only at the wound 
sites but also systemically (Brozovic 1977, Fujii et al. 1994, Komuro et al. 1998, Niemi et al. 
1998). To evaluate the activation of the coagulation and fibrinolytic systems perioperatively, 
highly specific and sensitive plasma markers for coagulation and fibrinolysis activity can be 
measured by means of recently developed ELISA-based immunoassays (Yoda and Tsukasa 
1981, Derlerck et al. 1987, Pelzer et al. 1988, Kluft and Verheijen 1990, Pelzer et al. 1991, 
Merlini et al. 1998). We wanted to find out how the hypercoagulable state, which is thought 
to be present in many patients, and the surgery itself affect the plasma markers, and also how 
anastomotic failures, which are expected to occur in some patients, further affect these 
markers. Furthermore, thrombosed anastomoses were subjected to histopathological and 
immunohistochemical analyses. More insight into the pathophysiology of clot formation and 
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its dissolution is needed to enable us to target optimal therapeutic interventions in 
microsurgery and thus to further reduce the risk of thrombotic events. 
 
While thrombosis remains a problem in microsurgery, thrombosis research has focused on 
antithrombotic and vasoactive agents (Buckley et al. 1994). Opinions about the use of 
antithrombotic agents in free flap surgery and also the practice differ around the world 
(Davies 1982, Salemark 1991, Siegel 1991). Systemic antithrombotic treatment with heparin, 
dextran and ASA is commonplace, as is local irrigation with heparinised saline. However, 
since systemic drugs may be used in excess and cause bleeding, research has lately focused on 
topically applied agents, and the search for the ideal topical antithrombotic agent continues 
(Cooley and Gould 1991, Das and Miller 1994). Recent studies on rat serosal mast cell -
derived heparin proteoglycans (HEP-PG) have shown that soluble or immobilised HEP-PG 
can completely inhibit collagen-induced platelet aggregation in human blood in vitro (Lassila 
et al. 1997). In this study we tested the inhibitory capacity of HEP-PG in vivo. 
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2. REVIEW OF THE LITERATURE 
 
2.1. The thrombotic process 
 
Thrombosis is a pathophysiological haemostatic response to vessel trauma. Numerous factors 
affect the thrombotic process in arteries, e.g. the amount of injury on the vessel wall, 
circulating blood platelets, the coagulation and fibrinolytic system and shear forces (Acland 
1973, Nievelstein and de Groot 1988, Lassila et al. 1990, Johnson et al. 1993, Maraganore 
1993, Barker et al. 1995, Ware and Coller 1995, Ruggeri 1997, Bassiouny et al. 1998). The 
most important initial interactions occur with circulating blood platelets and subendothelial 
layers of the injured vessel (Nievelstein and de Groot 1988, Tangelder et al. 1989, Ware and 
Coller 1995).   
 
Under normal conditions the intact endothelium presents a nonthrombogenic surface for 
flowing blood. Endothelial cells do not only form a barrier; they can also synthesise, secrete, 
bind and convert many substances involved in platelet function, coagulation and fibrinolysis.  
Prostacyclin and nitric oxide are two known potent inhibitors of platelet activation secreted by 
endothelial cells (Nievelstein and de Groot 1988, Ware and Coller 1995, Makhoul et al. 
1999). The intact endothelium can, however, become a site for platelet adherence, e.g. when 
inflammation, infection, cancer or some other chronic disease is present or when there is a  
toxic reaction to certain drugs (Brozovic 1977, Nievelstein and de Groot 1988, Zacharski et 
al. 1992, Donati 1995, Karpatkin et al. 1996, ten Cate et al. 1997, Makhoul et al.1999).  
 
In microvascular anastomoses, the needle holes are the most thrombogenic sites for platelet 
adherence (Acland 1973, Rosenbaum and Sundt 1977, Yo-dong et al. 1989). Once the 
endothelium is damaged and the subendothelium or deeper layers are exposed, platelets will 
rapidly adhere. Interstitial collagens of types I and III, which are located in the deeper layers, 
are known to be the strongest inducers of platelet adhesion and aggregation (Kehrel 1995). In 
small vessels, shear rates are high and platelet adhesion is enhanced (Ruggeri 1997). At high 
shear rates, von Willebrand factor (vWF) mediates the initial binding of platelets to the 
subendothelium via platelet membrane glycoprotein (GP) Ib (Nievelstein and de Groot 1988, 
Ruggeri and Ware 1993, Ware and Coller 1995, Ruggeri 1997). Platelets can also adhere to 
 13 
the exposed collagen direct via glycoprotein Ia/IIa-receptor (Ware and Coller 1995, Ruggeri 
1997). Subsequently, the platelets are activated and cover the exposed surfaces by spreading 
(Nightingale et al. 1980, Ruggeri and Ware 1993).  
 
vWF and fibrinogen bind to the activated platelets, linking one to another via glycoprotein 
IIb/IIIa-receptors in a process known as aggregation. Platelets are strongly activated when 
adhesion to collagen or other subendothelial elements occurs, but also when thrombin is 
formed (Ware and Coller 1995, Ruggeri 1997). Most of the activators are released and 
synthesised locally at the site of injury. Activated platelets themselves are capable of secreting 
proaggregatory substances, e.g. ADP and serotonin, of enzymatically converting arachinodic 
acid to thromboxane A2, and of generating thrombin on their membrane phospholipids, thus 
further promoting the growth of a sticky platelet plug (Nievelstein and de Groot 1988, 
Maraganore 1993, Ware and Coller 1995).  
 
The latticework of the thrombus is composed of fibrin strands. Activated platelets help to 
convert fibrinogen into fibrin via the generation of thrombin. Thrombin, being the clotting 
factor that is a potent physiological agonist activating platelets and inducing platelet 
aggregation, mediates the thrombotic process in arteries (Maraganore 1993, Ware and Coller 
1995). The amount of thrombin generated must be sufficient to overcome the inhibitory 
mechanisms of the nearby endothelial cells, and other local and systemic anticoagulant 
factors. Activated platelets accelerate thrombin formation on their membrane surface via the 
activation of factor X by factors IXa and VIIIa, and via the activation of prothrombin by 
factors Xa and Va. Membrane-associated thrombin generation is much faster than that 
occurring in plasma, and membrane phospholipids contribute mainly to procoagulant 
responses. Thrombin may also act locally at the site of arterial injury and cause vasospasm by  
inducing contraction of vascular smooth muscle (Brophy  et al. 1998). The initiation of 
platelet contraction, resulting in clot retraction, is also caused by thrombin (Ware and Coller 
1995).  
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2.2. Activation of blood coagulation and fibrinolysis 
 
The plasma markers for coagulation and fibrinolysis 
 
The complex system of blood coagulation cascade includes extrinsic or tissue factor pathway, 
which is currently thought to be the principal initiating pathway, intrinsic pathway and final 
common pathway leading to the generation of thrombin, see Figure 1 (Colman et al. 1994). 
Fibrinogen is an acute phase protein and the source of fibrin formation (Kwaan and Barlow 
1973, Brozovic 1977, Bennett and Towler 1985). Analysis of the generation of thrombin, the 
enzyme which converts fibrinogen into fibrin, includes fibrinopeptide A (FPA), prothrombin 
fragment 1+2 (F1+2), thrombin-antithrombin III complex (TAT) and activated protein C 
(APC) (Pelzer et al. 1988, Pelzer et al. 1991, Szczeklik et al. 1992, Merlini et al. 1998). When 
prothrombin is converted to thrombin via a proteolytic reaction, inactive prothrombin 
fragment 1+2 (F1+2) is released (Merlini et al. 1998). As thrombin converts fibrinogen into 
fibrin, fibrinopeptides A and B are released. The natural inhibitor of thrombin in plasma is 
antithrombin III, which forms a complex with thrombin (TAT) (Colman et al. 1994, Merlini 
et al. 1998). Thrombin can also bind to thrombomodulin on endothelial cells, leading to 
activation of protein C, which is a circulating anticoagulant (Fernandez et al. 1997, Merlini et 
al. 1998, Dahlbäck 2000). Besides these two inhibitors, tissue factor pathway inhibitor is of 
great importance in regulating coagulation activation (Broze 1995). 
 
The main function of the fibrinolytic system is to limit clot formation and degrade the fibrin 
deposits formed (Colman et al. 1994). The key enzyme capable of doing this is plasmin, 
which is formed from plasminogen after proteolytic activation (Lijnen and Collen 1995). 
Analysis of plasmin generation consists of D-dimer, a fibrin degradation product reflecting 
fibrinolysis, and the activity of tissue-type plasminogen activator (tPA) and plasminogen 
activator inhibitor-1 (PAI-1), the two regulators of fibrinolysis (Bennett and Towler 1985, 
Rånby et al. 1986, Derlerck et al. 1987, Kluft and Verheijen 1990, Lijnen and Collen 1995). 
D-dimer, reflecting in part thrombin action before clot formation as well as ongoing 
fibrinolysis, is formed after crosslinked fibrin is digested by plasmin (Colman et al. 1994). 
Tissue-type plasminogen activator is the main activator of circulating plasminogen and is 
released from endothelial cells. The activation is inhibited by plasminogen activator inhibitors 
(PAI), of which PAI-1 is the most important. These serve to facilitate fibrin formation during 
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the period when hemostatic plug is formed. Fibrinolytic system can also be inhibited via α2-
antiplasmin or thrombin-activatable fibrinolysis inhibitor (TAFI) (Colman et al. 1994, Bajzar 
et al. 1995). 
 
 
        
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
         
Figure 1. Schematic, simplified presentation of the coagulation and fibrinolytic systems 
relevant to this study. The plasma markers measured here are in shaded boxes. Of the 
inhibitors of the coagulation system only antithrombin is presented, and of the inhibitors of  
plasminogen activators only PAI-1, which is the most important. 
 
 
The hypercoagulable state 
 
Hypercoagulable states are classified as either primary or secondary. Primary 
hypercoagulable states are mostly due to inherited mutations of physiological antithrombotic 
factors leading to antithrombin/heparin disorders, protein C/protein S disorders or fibrinolytic 
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disorders. Secondary hypercoagulable states are mostly acquired, multifactorial and complex 
abnormalities of the haemostatic system. In secondary hypercoaglulable states diverse 
abnormalities in blood flow, blood composition and vessel wall can be found, e.g. in obesity, 
trauma, pregnancy, cancer and diabetes (Schafer 1997). According to a broad definition, in a 
hypercoagulable state the coagulation mechanism is activated in the blood without signs of 
thrombosis, and in the presence of additional prothrombotic stimuli it may develop into an 
overt thrombotic event (Schafer 1997, Merlini et al. 1998). Such additional prothrombotic 
stimuli could be stress, operation or other trauma, the last two subsequently followed by an 
acute phase reaction and a period of posttraumatic hypercoagulability (Brozovic 1977, 
Bennett and Towler 1985, Hoffmann 1991).   
  
The hypercoagulable or thrombophilic state in cancer patients has long been recognised 
(Kudrjashov et al. 1969, Yoda and Abe 1981, Rickles et al. 1992, Falanga et al. 1993, Donati 
1996, Karpatkin et al. 1996, Falanga and Rickles 1999, Kaviani and Organ Jr 1999). 
Procoagulant activation is revealed in many cancer patients by elevated levels of fibrinogen, 
fibrinopeptide A, F1+2, TAT and D-dimer (Yoda and Abe 1981, Zacharski et al. 1992, 
Falanga et al. 1993, Donati 1996, von Tempelhoff et al. 1997, Gouin-Thibault and Samama 
1999, López et al. 1999, Kalweit et al. 2000); in some patients also enhanced fibrinolytic 
activation is shown by intensified tPA and PAI activity (Zacharski et al. 1992, Schmitt et al. 
1997, von Tempelhoff et al. 1997, Carroll and Binder 1999). These markers are now known 
to be prognostically associated (Gouin-Thibault and Samama 1999). Enhanced 
anticoagulation therapy is therefore recommended in cancer patients in the context of surgery 
or chemotherapy (Rickles et al. 1992, Falanga et al. 1993, Donati 1995, Gondret et al. 1995, 
Zacharski and Ornstein 1998, Bona 1999, Gouin-Thibault and Samama 1999, Lee and Levine 
1999).  
  
In both acute and chronic cardiovascular diseases, the activation of blood coagulation can be 
measured by elevated fibrinogen, FPA, F1+2, TAT and /or D-dimer (Lassila et al. 1993, 
Merlini et al. 1994, Peltonen et al. 1995, Ernofsson et al. 1998, Merlini et al. 1998,  
Holmberg et al. 1999, López et al 1999). Here, treatment with LMWH was found to diminish 
both thrombin generation and activity (Ernofsson 1998). Thrombi stability is counteracted by 
the fibrinolytic system, tPA and PAI-1, which have also been reported to be related to well 
known cardiovascular risk factors, e.g. age, sex, blood pressure and centrally located body fat 
(Rånby et al. 1986, Sundell et al. 1989). Elevated levels of tPA have been recorded in 
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arteriosclerotic patients with aneurysmal and occlusive aorta (Shireman et al 1997). Also, 
upregulation of PAI-1 has been observed in patients with patent venous grafts (Peltonen et 
al.1996).  
 
In severe injuries such as pelvic and long bone fractures and abdominal and chest injuries, 
elevation of D-dimer has been reported in the majority of patients on the 1st day after trauma, 
the levels correlating with the injury severity score (Chen et al. 1999, Peetz et al 2000). PAI-1 
activity was also elevated in trauma patients at admission and was followed by a progressive 
decline from day 2 onwards (Chen et al. 1999). On the 1st day after burn trauma, both 
hypercoagulability and hyperfibrinolysis have occurred with elevated TAT, D-dimer and tPA, 
the hypercoagulability persisting for at least 1 week after trauma. Also, non-survivors were 
found to have higher levels of TAT and tPA than survivors on the 1st day after trauma 
(Garcia-Avello et al. 1998). Furthermore, in acute infections such as sepsis and endotoxaemia, 
activation of coagulation has been reported with elevated F1+2 and TAT levels (ten Cate et al. 
1997). 
 
The effect of surgery on coagulation and fibrinolysis 
 
During surgery, fibrinogen levels have been shown to decrease partly due to haemodilution 
and bleeding (Murray et al. 1988, Strauss et al. 1988, Fujii et al. 1994, Peltonen et al. 1996, 
Egli et al. 1997, Niemi et al. 1997, Peltonen et al. 1997), but a protracted increase in 
fibrinogen and FPA levels has been found to persist for a week or more after operation or 
trauma (Brozovic 1977, Bennett and Towler 1985, Fujii et al. 1994, Moor et al. 2000). Both 
thrombin generation, as measured by TAT and F1+2, and fibrinolysis, as measured by D-
dimer and tPA, are activated during surgery. The short-lived elevation of tPA is followed by a 
marked reduction on the 1st postoperative day. This condition, known as fibrinolytic 
shutdown, is mostly due to increased levels of PAI-1 (D’Angelo et al. 1985, Kluft et al. 
1985).  
 
During intracranial surgery, transient activation of coagulation has been reported with 
elevated TAT levels, as well as activation of fibrinolysis in response to trauma with elevated 
D-dimer, tPA and PAI-1 (Fujii et al. 1994, Peltonen et al. 1997). After laparoscopic 
cholecystectomy, activation of coagulation and increased fibrin turnover were found with 
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elevated F1+2, D-dimer and fibrin degradation products, whereas tPA activity was found to 
be increased intraoperatively (Rahr et al. 1999). Patients with pulmonary malignancies 
showed an intraoperative increase in F1+2 and D-dimer levels, whereas TAT remained 
unchanged during the operation (Kalweit et al. 2000). In neonates, increased levels of F1+2, 
tPA and PAI-1 were reported during cardiopulmonary bypass, and tPA remained elevated on 
the 3rd postoperative day when D-dimer levels were also elevated (Petäjä et al. 1996). After 
coronary artery bypass grafting, activation of coagulation was shown by elevated TAT on the 
3rd postoperative day, and an increase in plasminogen activator inhibitor-1 levels on the 1st 
postoperative day predicted graft failure (Moor et al. 2000). In orthopaedic surgery, elevated 
TAT on the 1st postoperative day was followed by a continuous decrease, whereas D-dimer 
decreased on the 1st postoperative day followed by a continuous increase up to the 8th 
postoperative day. D-dimer levels above 2 mg/l on the 4th postoperative day were related to 
thromboembolic complications, and D-dimer levels were monitored to adjust the dose of 
LMWH (Peetz et al. 2000). Anticoagulant treatment has also been shown to lower the levels 
of thrombin generation, F1+2 and TAT, during the perioperative period when there is 
considerable need for thrombosis prophylaxis (Amelsberg et al. 1992, van Wersch et al. 
1992). 
 
Activation of both coagulation and fibrinolysis is also seen during ischaemia and reperfusion. 
Activation of the coagulation system, measured by F1+2, TAT and soluble fibrin levels, was 
reported during open abdominal aortic surgery and persisted 1 week after the operation. Here, 
thrombin generation was stimulated mainly by ischaemia and reperfusion of the lower part of 
the body (Holmberg et al. 1999). After supraceliac aortic clamping, activation of fibrinolysis 
has been shown by elevated levels of tPA (Illig et al. 1997). Venous occlusion and the use of 
a tourniquet followed by ischaemia have been noted to enhance fibrinolysis by elevating D-
dimer, tPA and PAI levels, as well (Petäjä et al. 1987, Syrjälä et al. 1993, Niemi et al. 1996). 
 
Coagulation and fibrinolysis activation in thrombotic manifestations  
 
In acute myocardial infarction, thrombin generation is reflected in increased FPA, F1+2 and 
TAT levels in plasma, and a persistent hypercoagulable state, as measured with F1+2, 
continues for up to 6 months after the acute phase (Szczeklik et al. 1992, Merlini et al. 1994). 
In brain infarction, activation of coagulation and fibrinolysis varies in different subtypes: in 
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cardioembolic stroke, the elevation in TAT and D-dimer occurs within 48 h and persists for 1 
month, whereas in atherothrombotic stroke there is an increase only in D-dimer 1 week after 
onset (Takano et al. 1992). When patients with sudden arterial occlusion in the lower 
extremities were compared with patients with stable peripheral arterial occlusive disease, both 
coagulation and fibrinolysis, as measured by TAT, D-dimer, tPA and PAI-1 levels, were 
clearly activated during the occlusion, and increased levels of TAT and PAI-1 correlated with 
a poor outcome (Peltonen et al. 1995). Also, during acute deep vein thrombosis and 
pulmonary embolism, activation of coagulation can be detected as elevated F1+2 and TAT 
levels, and the activation of fibrinolysis as increasing levels of soluble D-dimer and tPA 
(Declerck et al. 1987, Pelzer et al. 1988, Boneu et al. 1991, Pelzer et al. 1991, Meissner et al. 
2000). Local thrombotic events in microsurgery have so far been studied in a limited number 
of patients, and here only two patients showed an increase in F1+2 and TAT, the markers of 
thrombin generation, at the time of threatening or obvious thrombosis and subsequent flap 
failure (Komuro et al. 1998).  
 
2.3. Antithrombotic agents and HEP-PG  
 
Antithrombotic agents act by reducing platelet aggregation, by inhibiting the coagulation 
cascade or by augmenting fibrinolysis (Tangelder et al. 1989, Johnson and Barker 1992, 
Maraganore 1993). In microsurgery, the agents are used either systemically or locally. The 
systemic agents inlude anticoagulants, antiplatelet drugs, plasma expanders and thrombolytic 
agents. In addition, agents causing peripheral vasodilatation are used. Locally administered 
agents include anticoagulants and thrombolytic agents, and are used either topically or as 
intra-arterial infusion (Salemark 1991, Siegel 1991, Johnson and Barker 1992).  
 
Heparins: unfractionated heparin and low-molecular-weight heparin 
 
Unfractionated heparin (UFH), the traditional golden standard anticoagulant, is a 
heterogeneous preparation of glycosaminoglycans derived from porcine intestinal mucosa 
with molecular weights ranging from 3000 to 30,000 (Murray et al. 1936, Ehrlich and Stivala 
1973, Salzman et al. 1980, Hirsh et al. 2001). It acts indirectly by inhibiting the conversion of 
fibrinogen into fibrin through interaction with antithrombin III (Salzman et al. 1980, Hirsh et 
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al. 1998). Heparin-antithrombin III complex inactivates thrombin and factor Xa and also 
many other factors in the clotting cascade (Jeske and Fareed 1993, Hirsh et al. 1998). The 
binding of heparin to antithrombin III is reversible and time-dependent, the half-life of its 
anticoagulant activity being 1-1.5 h (Ehrlich and Stivala 1973, Dawes 1993).  
 
Heparin can also reduce tissue factor production by binding to monocytes, and release tissue 
factor pathway inhibitor amplifying anticoagulation independent of antithrombin III (Dawes 
1993, Engelberg 1996). Endothelial cells take up heparin against a concentration gradient, and 
by increasing the negative surface charge heparin can also prevent platelet and red cell 
attachment to the endothelium (Hiebert and Jaques 1976). Heparin can lower plasma viscocity 
by lowering plasma fibrinogen levels, and it also enhances fibrinolysis (Ehrlich and Stivala 
1973, Engelberg 1996). 
 
The inhibitory capacity of heparin against thrombin could be beneficial in hindering tumour 
cell growth, as thrombin is known to enhance the progression of many tumours. The 
antioxidant effects of heparin may also play a role in malignancy (Karpatkin et al. 1996, 
Zacharski and Ornstein 1998).  Heparin has anti-inflammatory properties as well.  
 
Despite its anticoagulant properties, heparin has limited effect on the arterial thrombotic 
process. Both fibrin- and subendothelial matrix-bound thrombin have shown resistance to the 
inactivating effect of heparin-antithrombin III complex, and circulating heparin may thus be 
incapable of preventing thrombosis (Maraganore 1993, Hirsh et al. 1998). Heparin also exerts 
prothrombotic effects on platelets as a result of saturable, specific and reversible binding 
between heparin and platelets (Dawes 1993). Activated platelets secrete platelet factor 4, 
which is capable of neutralising the effect of heparin. This in part explains the limited 
antithrombotic effect of heparin on platelet-rich thrombi (Maraganore 1993, Ware and Coller 
1995, Arnljots et al. 1997). Also, in some diseases, e.g. ischaemic coronary syndromes, 
variable responses, even resistance, to heparin have been observed making the therapy 
unpredictable and less than optimal (Maraganore 1993, Hirsh et al. 2001). 
 
In clinical microsurgery, heparin has mostly been used systemically perioperatively to prevent 
thrombosis or in the event of obvious thrombosis, intraoperatively or at reoperation (Salemark 
1991, Johnson and Barker 1992). Complications during parenteral high-dose heparin therapy, 
haematoma and bleeding, have been reported to occur especially in combination with dextran 
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or ASA (Salemark 1991, Kroll et al. 1995). At some centres heparin is given systemically in 
low doses or boluses during the perioperative period, a practice considered safer as the rate of 
complications has not increased (Kroll et al. 1995). In experimental microsurgery, however, 
the effect of heparin boluses has been found doubtful (Arnljots and Bergqvist 1995). Heparin  
has also been administered successfully as a continuous, local intra-arterial infusion both 
experimentally and clinically (Fukui et al. 1989, May and Rothkopf 1989, Maeda et al. 1990). 
In a recent study, postoperative treatment with heparin alone or in combination with dextran 
did not improve the survival of free tissue transfers (Deutinger et al. 1998).  
 
Local instillation of heparin is commonly used at anastomosis either alone or in combination 
with other systemic agents, e.g. dextran (Salemark 1991, Johnson and Barker 1992). 
Experimental studies have shown that local instillation of heparin hinders thrombosis in 
microanastomoses and traumatised vessels, although contradictory results have also been 
obtained (Rosenbaum and Sundt 1977, Sinclair 1980, Zinberg et al. 1989, Wieslander and 
Dougan 1990, Cox et al. 1992, Das and Miller 1994, Chen et al. 1996). Applied topically, in 
concentrations of at least 50 U/ml, heparin has successfully inhibited thrombin activity on the 
damaged vessel wall, but this was not found when heparin was used systemically in optimal, 
safe concentrations (Johnson and Barker 1992). Administered systemically, heparin is capable 
of inhibiting only soluble thrombin, not thrombin already bound to fibrin and subendothelial 
matrix; therefore the application of heparin locally at anastomosis could be a valid option.  
 
Low molecular-weight heparins (LMWH) are chemically obtained fragments of 
unfractionated heparin with a mean molecular weight of 5000. Their half-life is 2-4 times 
longer than that of UFH; they have dose-independent clearance and are almost completely 
absorbed when injected subcutaneously, thus making the anticoagulant response more 
predictable than that of UFH (Bergqvist et al. 1983, Bergqvist 1996, Weitz 1997, Hirsh et al. 
1998, Nader et al. 1999).  Like unfractionated heparins, LMWH bind to and activate 
antithrombin III, but LWMH have greater activity against factor Xa than against factor IIa 
(thrombin) when compared with UFH (Serra et al. 1997, Hirsh et al. 1998). If thrombin is 
fibrin-bound, LMWH cannot inactivate it, either. Also, like unfractionated heparin, LMWH 
can release tissue factor pathway inhibitor, thus enhancing their anticoagulant activity (Weitz 
1997). The selective decline in circulating antithrombin and tissue factor pathway inhibitor 
during infusion of UFH, but not during subcutaneous LMWH treatment, might also explain 
the better efficacy of LMWH over UFH (Hansen J-B and Sandset PM 1998). The LMWH 
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affinity for cell receptors is lower than that of UFH, and their effects are more likely mediated 
through mechanisms other than cellular interactions, which accounts for their better 
bioavailability (Dawes 1993, Weitz 1997). LMWH have also been shown to be less active 
than UFH in inducing platelet aggregation (Salzman et al. 1980). LMWH have fewer side 
effects than UFH. They have been reported to cause less bleeding, since platelet function and 
the platelet-vessel wall interaction are less inhibited, and microvascular permeability is not 
increased (Weitz 1997, Zacharski and Ornstein 1998). Moreover, the risk of heparin-induced 
thrombocytopaenia, as well as osteoporosis, seems to be lower when LMWH are used (Weitz 
1997). LMWH, like UFH, possess anti-inflammatory properties (Downing et al.1998). 
 
In clinics, LMWH are used as subcutaneous injections to prevent and treat thromboembolic 
events, that is, deep vein thrombosis and pulmonary embolism, in the context of surgery and 
trauma and also to treat unstable angina and acute myocardial ischaemia (Gondret et al. 1995, 
Weitz 1997, Turpie 1999). To date, their effect in hindering arterial thrombosis at the level of 
microanastomoses, whether in systemic or topical use, has been demonstrated only in animal 
studies (Zhang and Wieslander 1992, Zhang et al. 1993, Chen et al. 1995, Kroll et al. 1995).  
 
Antiplatelet agents 
 
Acetylsalicylic acid (ASA) is the traditional, most widely used antiplatelet agent (Nichter and 
Bindiger 1988, Tangelder et al. 1989, Johnson and Barker 1992, Ware and Coller 1995). 
Platelet aggregation is inhibited through the arachinodic acid pathway. Via the irreversible 
inhibition of cyclo-oxygenase prostaglandin synthesis and the production of 
proaggregant/vasoconstrictor, thromboxane A2 is blocked for the whole lifespan of platelets 
treated with small amounts (> 50 mg) of peroral ASA. A sign of the antiplatelet effect is 
prolonged bleeding time. Large doses of ASA inhibit cyclo-oxygenase -dependent 
prostacyclin production in endothelial cells but only temporarily, due to rapid synthesis. As 
anucleic platelets lack the machinery for synthesis, the effect of ASA is eliminated only in 
platelets newly liberated from bone marrow megakaryocytes (Ware and Coller 1995).    
 
With its 25-30% secondary preventive efficacy on atherothrombotic events clinics have long 
used ASA in prevention of cardio- and cerebrovascular diseases [Antithrombotic Trialists’ 
(ATT) Collaboration 2001]. As a new antiplatelet alternative, clopidogrel, an ADP-receptor 
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antagonist, offers secondary prevention for patients insensitive or unresponsive to ASA 
(Gachet 2000).  In experimental microsurgical studies, ASA has effectively hindered platelet 
aggregation but not necessarily thrombus formation (Folts et al. 1976, Rosenbaum and Sundt 
1977, Cooley et al. 1987, Buckley et al. 1994). Many microsurgical centres use ASA 
perioperatively, often in combination with dextran. (Salemark 1991, Siegel 1991, Johnson and 
Barker 1992). 
 
Other antiplatelet agents are prostacyclin and its analogues. Prostacyclin is a platelet 
antiaggregator endogenously formed by endothelial cells from arachinodic acid (Tangelder et 
al. 1989). It acts by increasing the level of c-AMP in platelets, thus inhibiting the activation, 
as well as aggregation, of platelets. It is also vasodilatory. As exogenous prostacyclin is 
unstable and has a short half-life, more stable analogues have been developed. Dipyridamole, 
a phosphodiesterase inhibitor, works not only on the level of c-AMP but by raising the level 
of platelet antagonist adenosine in plasma. In experimental microsurgical studies the effects 
have been contradictory, and only some centres use them, either postoperatively alone or in 
combination with ASA  (Salemark 1991, Salemark et al. 1991, Savoie et al. 1991, Siegel 
1991, Salemark et al. 1995).  
 
Dextran 
 
Dextran is a polysaccharide normally used as a plasma expander. It has both low-molecular 
weight (40,000) and high molecular weight forms (70,000) (Ljungström K-G 1988). Its 
antithrombotic properties are due to a reduction in platelet adhesion, a decrease in factor VIII-
related antigen activity, a reduction in platelet aggregation and a decrease in blood viscosity. 
Fibrin formation and stabilisation are also impaired (Batlle et al 1985, Wieslander et al. 1986, 
Johnson and Barker 1992, Wolfort et al. 1992, Buckley et al. 1994). Dextran causes fewer 
haemorrhagic complications than heparin. Due to its antigenicity, however, allergic reactions 
can occur, but they are rare (Ljungström K-G 1988, Siegel 1991). 
  
The antithrombotic efficacy of dextran in preventing deep vein thrombosis and pulmonary 
enbolism in the context of surgery is well known (Ljungström K-G 1988). In experimental 
microsurgery, both short- and long-term studies have shown that dextran is effective in 
hindering arterial thrombosis either alone or in combination with other antithrombotic agents 
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(Savoie et al. 1991, Wolfort et al. 1992, Zhang and Wieslander 1993, Buckley et al. 1994, 
Rooks et al. 1994). In clinical microsurgical pratice, dextran is widely used intra- and 
postoperatively alone or in combination with heparin or ASA (Salemark 1991, Siegel 1991). 
 
Thrombolytic agents 
 
The thrombolytic drugs streptokinase and tPA activate the endogenous fibrinolytic system. 
They activate fibrinolysis by converting plasminogen to plasmin. The proteolytic enzyme 
plasmin then lyses fibrin in clots. Streptokinase activates plasminogen in circulation and tPA 
on the clot surface. Streptokinase lacks selectivity for fibrin, causing fibrinogen depletion. 
Streptokinase can thus cause complications such as bleeding and allergic reactions (Johnson 
and Tillett 1952, Goldberg et al. 1989, Rooks et al. 1994, Hashim et al. 1996). The advantages 
of tissue plasminogen activator over streptokinase are that it binds specifically to fibrin and 
not to circulating fibrinogen, initiating fibrinolysis only locally and leaving fibrinogen largely 
undepleted, which diminishes the risk of haemorrage. Also, tPA is nonantigenic and has a 
shorter half-life than streptokinase (Hashim et al. 1996, Lykoudis et al. 2000). 
 
In routine clinical practice, they are used to treat acute myocardial infarction. Microsurgical 
experimental studies have demonstrated their efficacy in hindering stable thrombus formation 
or in lysing clots either alone or in combination with other antithrombotic agents, but 
contradictory results have also been presented (Johnson and Tillett 1952, Levy et al. 1991, 
Savoie et al. 1991, Arnljots et al. 1994, Rooks et al. 1994, Chen et al. 1995).  In clinical 
microsurgery, these agents are used mainly in the event of manifest thrombosis (Fukui et al. 
1989, Goldberg et al. 1989, Salemark 1991, Siegel 1991, Hussein et al. 1996, Theile and 
Coombs 1996).  
 
Other agents 
 
A variety of other substances have been tested experimentally and found to improve 
microvascular patency. The most potent inhibitors of thrombin are hirudin and its 
recombinant form (Arnljots and Bergqvist 1995, Zhang and Wieslander 1996, Hirsh and 
Weitz 1999). Like heparin, hirudin is capable of inhibiting circulating thrombin in plasma. 
Hirudin exerts its inhibitory effect on thrombin via a direct active-site mechanism whereas 
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heparin needs a cofactor, antithrombin III. In addition to this, hirudin can inhibit fibrin-bound 
thrombin but heparin can only attack the circulating enzyme. The antithrombotic effects of 
hirudin have been found even after its plasma clearance, implying that treatment with single 
boluses could be effective in hindering thrombus formation. 
  
Tissue factor pathway inhibitor, a protein inhibitor naturally secreted from platelets and 
bound to plasma lipoproteins, exerts its effect on the extrinsic pathway of coagulation by 
binding to and inhibiting tissue factor and factor VIIa and also factor Xa (Ware and Coller 
1995). It has specific binding sites on the injured vessel wall when topically applied, and as a 
topical antithrombotic agent it is more effective than heparin (Ozbeck et al. 1995). In a large, 
multicentre clinical study, topically applied recombinant human tissue factor pathway 
inhibitor was as efficacious as locally instilled heparin in preventing thrombosis in free flap 
surgery (Khouri et al. 2001). 
 
Another agent that works on the level of the extrinsic pathway is active site-inactivated factor 
VIIa (Arnljots et al. 1997). Normally the extrinsic pathway of coagulation is initiated after 
tissue factor from the injured vessel wall binds to factor VIIa, the complex further activating 
factor IX and factor X, and finally leading to thrombin generation. Here, thrombin formation 
could be blocked at the very first step by using modified factor VIIa, which is capable of 
binding to tissue factor but has an inactivated enzymatic site. Here, too, the antithrombotic 
effect of the agent when topically applied was better than that of heparin boluses and there 
were no haemorragic side effects. A recent study found this effect with systemic 
administration, too (Söderström et al. 2001). An earlier study, however, reported an increase 
in duration and episodes of anastomotic bleeding (Sørensen et al. 1999). 
 
Pentoxifylline, a haemorrheologic agent normally used in clinics to treat claudication,  
increases erythrocyte flexibility and microcirculatory flow, and reduces blood viscosity.  It 
also decreases platelet hyperactivity, and may lower fibrinogen levels. Pentoxyfylline has 
further been shown to decrease levels of platelet-activating factor and thereby to reduce the 
amount of tissue injury caused by ischaemia-reperfusion (Adams et al. 1995). A significant 
improvement on patencies has been seen in severe trauma models in animals treated with this 
agent, and it is used at some microsurgical centres (Siegel 1991, Kronen et al. 1994).  
 
In addition to these, vasodilatory agents have been found to improve microvascular patency. 
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Phentolamine, which dilates vascular smooth muscle, has been beneficial in experimental 
studies when topically applied (Reichel et al. 1988). At clinics some centres use vasodilators 
intraoperatively, e.g. xylocaine and papaverine, to treat spasm or postoperatively, e.g. 
chlorpromatzine, to enhance peripheral circulation (Siegel 1991, Khouri 1992). 
 
HEP-PG 
 
The soluble heparin proteoglycans (HEP-PG) are released from mast cell cytoplasmic 
secretory granules after their exocytosis, and have a molecular weight of 750 000 (Yurt et al. 
1977). They contain heparin and chondroitin sulphate glycosaminoglycan chains, one HEP-
PG monomer consisting of approximately 10 heparin glycosaminoglycan chains (MW 75 
000) (Lindstedt et al. 1992, Lassila et al. 1997). In vitro HEP-PG were found to totally inhibit 
collagen-induced platelet aggregation and subsequent serotonin release, due to the heparin 
glycosaminoglycan component and HEP-PG macromolecular structure. This inhibitory effect 
is lacking or minimal in standard heparins, see Table 1. HEP-PG did not block glycoprotein 
Ia/IIa-mediated platelet adhesion at high shear rates, but they did reduce GPIa/IIa –induced 
activation. Also, thrombin-induced platelet aggregation and von Willebrand factor binding to 
glycoprotein receptor IIb/IIIa were reduced (Lassila et al. 1997). Recently, similar results 
were obtained with HEP-PG immobilised together with collagen (Kauhanen et al. 1998). 
HEP-PG inhibited release reaction from the adherent platelets as well. HEP-PG have further 
been shown to have an inhibitory effect on rat aortic smooth muscle cell proliferation (Wang 
and Kovanen 1999). When cutaneous mast cells were stimulated by subjecting them to an 
allergenic challenge, bleeding time was prolonged and thrombin generation reduced 
(Kauhanen et al. 1998). 
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TABLE 1. Comparison of unfractionated heparin (UFH), low-molecular-weight heparin (LMWH) and  
heparin-proteoglycans (HEP-PG).    
    
    
 UFH LMWH HEP-PG 
    
Molecular weight (kDa) 3-30 1-10 750 
    
Inhibition of coagulation in plasma +++ ++ + 
    
Dependence of antithrombin III in the antithrombotic effect +++ +++ - 
    
Inhibitory effect of the platelet interaction with collagen (+) - +++ 
    
Binding to von Willebrand factor + ++ +++ 
    
 
The search for an ideal topical antithrombotic agent has been going on for a long time. This 
ideal topical antithrombotic agent, according to Cooley and Gould, would bind readily to the 
injured vessel lumen, not further injure the endothelium, effectively hinder thrombotic 
occlusion, maintain patency until the vessel is reendothelialised, not disturb the natural 
healing process, and not have harmful long-term effects (Cooley and Gould 1991). The newly 
found rat serosal mast cell-derived HEP-PG, which completely inhibit collagen-induced 
platelet aggregation in human blood, could potentially fulfil these criteria (Lassila et al. 1997).  
 
2.4. Experimental thrombosis research 
 
Experimental thrombosis models 
 
In early experimental studies, thrombosis was induced with the aid of proteolytic enzymes 
trypsin and papain (Eagle and Harris 1937), chemical agents such as sodium ricinoleate and 
thrombin (Solandt and Best 1938, Warner et al. 1939) or sclerosing agents such as sodium 
morrhuate (Johnson and Tillett 1952). A thrombus was also produced by using magnesium 
and magnesium-aluminium wire (Stone and Lord 1951), polyethylene tubing (Friedman and 
Byers 1961), or biolaser or electrical current (Arfors et al. 1966, Reber 1966). Also, inserting 
a plastic cylinder externally into dog’s coronary arteries resulted in stenosis, leading to 
reduced flow and subsequent platelet aggregation (Folts et al. 1976).  
 
 28 
In the early years of clinical microsurgery Acland made experiments on the effects of 
different surgical traumas on rat femoral vessels including pinching, pulling, scraping, 
incising and suturing the vessels, and came to the conclusion that the greatest trauma was 
created by an incision closed by a single suture (Acland 1973). The anastomosis model was 
one of the first to be used and still is favoured in various contexts (Baxter et al. 1972, Acland 
and Trachtenberg 1977, Rosenbaum and Sundt 1977, Nightingale et al. 1980, Wieslander et 
al. 1982, Yu-dong et al. 1989, Johnson et al. 1993, Boeckx et al. 1994, Sigurbjörnsson et al. 
1994). Since then, various new models have been developed and used to study thrombus 
formation and the effects of trauma and to test the effect of new antithrombotic agents. The 
arterial inversion graft model has been used alone or in combination with crush injury (Kersh 
et al. 1989,  Kronen et al. 1994). Crush injury combined with arteriotomy, intimal abrasion 
and stasis (Davidson et al. 1990, Buckley et al. 1994), crush injury and venotomy (L evy et al. 
1991), crush-avulsion injury (Cooley et al. 1987, Rooks et al. 1993, Fu et al. 1995) and crush 
injury alone or combined with anastomosis have all been used during the past decade 
(Stockmans et al. 1991, Chen et al. 1996). Other methods have included arteriotomy 
combined with intimectomy (Wieslander et al. 1990, Zhang and Wieslander 1996), 
arteriotomy and an inverted flap (Barker et al. 1992), anastomosis with a twisted pedicle 
(Ozbek et al. 1994, Atchabahian and Masquelet 1996), intimal abrasion with a twisted pedicle 
(Brown et al. 1995), clamp injury alone or combined with stasis (Jackiewicz et al. 1996, 
Thomson et al. 1998), clip ligature (Kashyap et al. 2001), the erroneous placing of a stitch in a 
vein and venous anastomosis with a knotted sut ure (Lan et al. 1992, Tonken et al. 1995). 
Thrombosis has also been induced photochemically with green light and rose Bengal injection 
(Kikuchi et al. 1998). 
 
Methods for thrombosis evaluation 
 
To start with, light microscopy with different stainings was used to evaluate the healing 
process and histopathology of microanastomoses or to compare the effect of different 
irrigation solutions or pharmacological agents (Baxter et al. 1972, Acland and Trachtenberg 
1977, Acland et al. 1980). Later, scanning electron microscopy was often employed in the 
evaluation of trauma-induced endothelial changes or thrombus formation, in the evaluation of 
the normal healing process of microvascular anastomoses or endothelial regeneration of 
microvascular prostheses and in studies of vascular intimal thickening (Dujovny et al. 1979, 
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Nightingale et al. 1980, Cooley et al. 1987, Levy et al. 1991, Savoie et al. 1991, Boeckx et al. 
1994, Fu et al. 1995, Lanzetta and Owen 1996, Kikuchi et al. 1998, Kashyap et al. 2001). 
Electron microscopy has also been applied to evaluate regeneration of the endothelium with 
its intracytoplasmic structure, intercellular junctions and smooth muscle cells after clamping 
injury and in studies of myofibroblasts in intimal hyperplasia (Jackiewicz et al. 1996, Yang et 
al. 1998). 
 
During the last two decades, radiolabelled platelets have been used in studies of thrombus 
kinetics in injured vessels (Wieslander et al. 1982, Wieslander et al. 1986,  Lassila et al. 1990, 
Stockmans et al. 1991, Zhang et al. 1993). The new methods involve direct on line 
visualisation of thrombus formation at the anastomosis area and measurements of emboli in 
the downstream microcirculation by means of video camera, monitor and recorder (Barker et 
al. 1992, Andresen et al. 1994, O´Shaughnessy et al. 1994, Barker et al. 1995, Sørensen et al. 
1999).  
 
2.5. Histopathology of microvascular anastomoses 
 
Histopathology in experimental microvascular models 
 
Baxter and his colleagues studied the histopathology of rabbit microanastomoses in biopsies 
obtained from the 3rd postoperative day up to the 18th postoperative week (Baxter et al. 
1972). If the cut vessel edges were in accurate apposition, only a thin layer of mural thrombus 
was found on the luminal surface from the 3rd day on, and the thrombus shrank during the 
2nd week followed by invasion of smooth muscle cells, elastin and collagen fibres, and 
endothelial cells. If accurate alignment was not achieved, the thrombus spread and, in some 
cases, became obstructive. Some of these obstructive thrombi recanalised after a week, but in 
others the recanalisation failed to take place. Medial disruption was greatest in the vessels that 
had too many sutures, and were unevenly positioned, causing tension. The normal restoration 
process comprising subintimal hyperplasia started in the 1st postoperative week, and was 
dependent on the amount of viable media; loss of media led to thrombosis without 
regeneration in one-third or more cases.         
 
Acland and Trachtenberg studied the histology of longitudinally cut sections of patent rat 
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anastomoses, from 1 h to 3 weeks postoperatively (Acland and Trachtenberg 1977). They 
found intimal loss all the way between the clamps, but the internal elastic lamina was intact. 
In most of the samples, medial necrosis was widespread, extending for 2 mm on either side of 
the anastomosis area; as in the study made by Baxter et al. it was not found to correlate with 
suture placement. No regeneration or invasion of the necrotic media was seen up to the 3rd 
postoperative week. Depending on the time of sample collection, thrombi caused narrowing 
of the lumen at 1 h in most samples; after a week the narrowing was due to fibrous ingrowth 
in some samples. 
 
As endothelial damage was widespread on patent anastomoses in early histological studies, 
the cause was sought by means of comparative histological work on different irrigation 
solutions. The conclusion reached was that normal saline produced more severe endothelial 
damage, and cytoplasmic and nuclear changes, than did physiological buffered solutions such 
as lactated Ringer´s solution and Normosol (Acland et al. 1980). However, all the vessels 
revealed endothelial hyperplasia and platelet deposits, even control vessels that were only 
dissected free from the surroundings without the use of irrigation solution.  
 
Lidman and Daniel studied the normal healing process of rabbits´ microanastomoses during a 
3-month period (Lidman and Daniel 1981). At first, the damage associated with the 
anastomoses included endothelial loss, and necrosis in the media and adventitia under the ties, 
but the internal elastic lamina was mostly intact. During the follow-up period the endothelium 
and adventitia were restored, but the part of the media that was necrotic failed to regenerate. 
The vessel wall maintained its thickness thanks to reactive intimal hyperplasia. A thick layer 
of cells with elongated nuclei, resembling smooth muscle cells, developed in the vessel wall 
between a single endothelial cell layer and medial smooth muscle cells. Later, in a 12-month 
follow-up study showed that the temporary arterial hypertrophic response was greatest at the 
3rd month postoperatively, declining thereafter (Lidman et al. 1984).  
 
The development of intimal hyperplasia by myofibroblasts in healing microanastomoses has 
been studied in greater detail recently with the aid of electron microscopy. In that study, 
spindleshaped immature fibroblasts were seen on the intima at the end of the 1st postoperative 
week, and only after a month did they become mature (Yang et al. 1998). In another study on 
endothelial injury, smooth muscle cell migration from the media to the neointima occurred a 
week after the injury; the formation of neointima reached its maximun 3 weeks after the 
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injury and remained unchanged for up to 42 days (Kikuchi et al. 1998). A recent test on the 
inhibitory effect of platelet-derived growth factor antagonist on intimal hyperplasia in a rat 
carotid artery injury model found that the beneficial effect was lost after 2 weeks of treatment 
(Leppänen et al. 2000). 
 
When microvascular anastomosis was performed in the presence of bacterial infection, the 
intima remained unaffected, but the media and adventitia became oedematous and, in 
thrombosed arteries, highly fibrotic, causing constriction of the vessel ( Luk et al. 1987).  
 
Histopathology of human microvascular anastomoses 
 
Two large-scale histopathological studies of human microvascular anastomoses were 
conducted in the 1980s and 1990s. The first, by Lidman and Daniel, consisted of 45 vessel 
biopsies, both arterial and venous, taken during free flap transfers and 32 taken during 
replantations. In addition, 10 anastomoses were harvested during free flap transfers, mostly at 
the time of reoperation, and 14 during replantations (Lidman and Daniel 1981). The vessel 
biopsies showed intact endothelium and internal elastic lamina in most of the free flap 
transfers during primary operations, but only in less than half of the cases during secondary 
operations. Moreover, inflammation and thrombosis were found in about half of the cases 
during the secondary operation. Enhanced intimal proliferation on the recipient vessels was 
observed in more than half of the cases during both primary and secondary operations. When 
the biopsies were taken from replantations, thrombi and inflammation and also damaged 
endothelium and internal elastic lamina, were found in most of the replantation cases during 
secondary operations, but in many during primary operations, too. Bleeding into the media 
was also evident in some cases, as were old intimal proliferations on the distal vessels in some 
of the primary replantations. Evaluation of the failed anastomoses from both the free flap 
transfers and the replantations showed thrombi, inflammation, endothelial damage, and 
intimal proliferations present in most of the anastomoses, the technical quality was in general 
good.  
 
 The other study of vessel pathology examined a series of 100 toe transplantations; the 
samples were obtained from uncomplicated anastomoses, vasospastic areas or sites of thrombi 
(Gu et al. 1992). In over half of the cases, primary histology was normal, and only a few of 
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them had postoperative circulatory crisis. Thickness of the intima was seen in 21 cases, but 
none of these had circulatory problems. However, a circulatory crisis occurred in 10 out of 14 
cases with acute or chronic inflammation of the vascular wall; most of these had a history of 
veinpuncture and some had previous surgical trauma as well. Only five transplantations 
failed, and in all but one of these, the primary histopathology revealed inflammation of the 
vascular wall.  
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3. AIMS OF THE STUDY 
 
The general aim of our studies was to evaluate the occurrence of acute arterial thrombosis in 
association with microsurgery, a field in which anastomotic failures are still a problem. As 
new sensitive, coagulation markers have already been tested in other thrombotic 
manifestations, the focus of our interest was on assessing their capacity to detect procoagulant 
states and local thrombosis developing intra- or postoperatively. By using specific, 
immunohistochemical staining we hoped to gain further insight into the local pathogenesis of 
the thrombi formed in the failed anastomoses. Also, as HEP-PG have recently shown in vitro 
to have promise in blocking thrombus growth, we wanted to test their antithrombotic effect in 
vivo in microvascular anastomoses. 
    
The specific aims of these studies were as follows: 
 
1.  To investigate the activation of coagulation and fibrinolysis during microsurgery, and 
the association of plasma markers with clinical thrombotic manifestations. 
 
2.  To evaluate the locally formed thrombi by immunohistochemical methods; 
 specifically accumulation of platelets and fibrin on the damaged vascular tissue. 
 
3. To conduct experimental studies on the inhibitory effect of HEP-PG on platelet-
collagen interaction in a high shear rate microvascular anastomosis model in rat 
common femoral arteries. 
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4. MATERIALS AND METHODS 
 
4.1. PATIENTS AND METHODS; CLINICAL PART - Studies I, 
II and III 
 
4.1. Patients and microsurgical procedures (Studies I, II and III) 
 
These studies were carried out during a period of 4 months in 1998 at the Department of 
Plastic Surgery (studies I, II and III), and at the Fourth Department of Surgery (study I), 
Helsinki University Central Hospital. The coagulation and fibrinolytic assays were performed 
in consecutive patients in the three following groups: patients requiring late breast 
reconstructions, patients with trauma or chronic ulcer in the lower extremities and patients 
with cancer in the oral cavity or the extremities [study I (including four patients with 
previously unpublished data), studies II and III]. After permission the blood samples for 
coagulation and fibrinolytic parameters were collected from a total of 24 informed patients 
with the approval of the local Ethical Committee. A vessel sample was taken from six of these 
patients for study I and additionally from seven patients with a non-functioning anastomosis 
that was resected during primary surgery or reoperation (study I). All patients had been given 
thrombosis prophylaxis according to the protocol below, except one patient in study I from 
whom only a vessel sample was taken. The patients were interviewed about their smoking 
habits, chronic diseases, medication and previous history of thromboembolism, i.e. deep 
venous thrombosis (DVT) or pulmonary embolism (PE). Information was also collected from 
medical records. The characteristics of the patients from whom the coagulation and 
fibrinolytic markers were analysed are listed in Table 2.   
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TABLE 2. Characteristics of the patients in groups I-III. Group I = late breast reconstructions with a free
 
TRAM flap, group II = free flap reconstructions for lower extremity trauma or chronic ulcer, group III =  
immediate cancer reconstructions with free flaps. The values are mean (range) or number of patients. 
GROUP I
 
GROUP II
 
GROUP III
 
n = 9 n = 8 n = 7 
Age (yr) 51 (36-74) 45 (19-69) 57 (31-80) 
Sex (female/male) 9/- 3/5 3/4 
Weight (kg) 68 (53-84) 70 (50-85) 67 (47-81) 
Smokers (ex & current) 1 2 5 
Previous DVT/PE - - - 
Family background DVT/PE -  1 1 
Chronic diseases
 
       cardiovascular 2 1 1 
       chronic obstructive pulmonary disease 1 1 - 
       systemic lupus erythematosus  - 1 - 
       Waldenström´s macroglobulinaemia - - 1 
Chronic medication 
       acetylsalicylic acid
 
-
 
-
 
-
 
       NSAID 2 4 2 
       warfarin - - 1 
       nitrates, digitalis, b-blockers, ACE inhibitors 2 - 1 
       cortisone - 1 - 
       cytostatics - - 1 
Preoperative trauma
 
       < 3 months - 4 - 
       3-12 months - 1 - 
Preoperative surgical intervention 
       < 3 months: - biopsy - - 6 
                         - tumour removal, other - 5 1 
       3-12 months - 2 - 
DVT = deep venous thrombosis, PE = pulmonary embolism, NSAID = non-steroid anti-inflmmatory drugs. 
All patients in studies I-III, except one patient in study I from whom only a vessel sample was 
taken, were given thrombosis prophylaxis with dalteparin (Fragmin®, Pharmacia Upjohn) 2-
12 h before the operation. The level of anti-factor Xa activity was assessed as the indicator of 
the efficacy of LMWH. Blood loss during the operation was replaced by giving the patients 
 36 
crystalloids and 6% hydroxyethylstarch ad 20 ml/kg (HES, Plasmafusin®, Pharmacia 
Upjohn) and, when appropriate, blood and albumin 4%. Our protocol does not include 
intraoperative use of Dextran. In all patients, the anastomosis region was irrigated with 
heparinised (25 U/ml) saline solution during primary surgery, as well. The overall events 
during surgery in patients subjected to the coagulation and fibrinolytic assays are presented in 
Table 3.  
    
    
TABLE 3. Overall events during surgery in groups I-III. Group I = TRAM patients, group II =    
patients with lower extremity trauma, group III = cancer patients. The values are mean (range)  
and / or number of cases. * = between artery – vein graft. ** = one of the patients with venous 
thrombosis also had an arterial thrombosis. 
    
    
 GROUP I GROUP II GROUP III 
 n = 9 N = 8 n = 7 
    
Operation time (min) 423 (275-545)  304 (200-390) 431 (330-555) 
    
Ischaemia time (min) 92 (45-180) 62 (36-113) 119 (82-188) 
    
Tourniquet time (min) - 37 (8-87) / 6 74 (44-127) 
    
Intraoperative bleeding (ml) 1050 (350-2000) 960 (300-3000) 1386 (400-2200) 
    
Blood transfusion (units)    
       Intraoperatively 3.0 (1-6) / 7 2.8 (1-4) / 5 3.3 (2-6) 
       Postoperatively 1.7 (1-4) / 6 1.7 (1-2) / 3 1.3 (1-2) / 3 
       1st postoperative day 1.3 (1-2) / 3 2 / 1 2.3 (1-4) / 3 
    
Albumin transfusion (ml) 625 (500-1000) / 4 875 (500-1000) / 4 667 (500-1000) / 3 
    
Anastomosis technique    
       End-to-end 9 - 6 
       End-to-side - 8 1 
    
Vein graft 3 1 2 
    
Intraoperative thrombosis    
       Arterial: obvious 3 1 1* 
                     suspected 2 - - 
       Venous 2** - - 
    
Reoperation    
       X 1 - 2 1 
       X 2 1 1 - 
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The TRAM group (study I) 
 
The TRAM group consisted of nine patients who underwent delayed breast reconstruction 
with a transversus rectus abdominis musculocutaneous (TRAM) flap (five of the patients in 
study I, the other patients’ unpublished data). The breast reconstruction was made 3-6 yr after 
mastectomy with the exception of one, which was made 21 yr afterwards. Eight of the 
patients had received postoperative irradiation, and one had had a liver metastasis removed 2 
yr earlier; follow-up was uneventful. The TRAM reconstruction was made, as described 
earlier (Asko-Seljavaara 1998, Nieminen et al. 1999), bilaterally in one of the patients and 
unilaterally in all the others. Three patients needed vein grafts due to resection of 
intraoperatively non-functioning or thrombosed anastomoses, with subsequent loss of the 
vessel required for anastomosis. The first two patients (arterial anastomoses) were given 
Heparin® 5000 IU iv (Leiras, Helsinki, Finland) after vein grafting; the third patient (venous 
anastomosis) received an extra dose of dalteparin 2500 IU sc. One other patient was given 
heparin after the artery had been reanastomosed due to intraoperative thrombosis. Two 
patients with intraoperative thrombosis were treated only surgically by resecting and redoing 
the anastomosis. The patients with intraoperative thrombosis were divided into two subgroups 
for the statistical analysis: 1) those with arterial and venous thrombosis, both obvious and 
suspected; and 2) those with obvious arterial thrombosis only.  
 
The lower extremity trauma group (study II) 
 
This group consisted of eight patients receiving different types of free flaps in the lower 
extremities due to trauma or chronic ulcer (study II). The defects of the lower extremities 
were due to recent (within 3 months) complicated fracture of the leg in three patients and 
open calcaneal fracture in one patient; an old (10 months) complicated tibial fracture with 
osteitis and pseudoarthrosis in one; an ulcer in the foot after metatarsal amputation because of 
arteriosclerosis obliterans (ASO) in one; and other previous injuries in two patients. Four 
patients were treated with antibiotics before surgery, and preoperative infection parameters 
(CRP, leukocytes) were within normal limits or just slightly above normal in all eight 
patients. The donor sites for reconstructions were as follows: gracilis in four patients, and 
latissimus dorsi (LD) in one, LD with scapular rim in one, radial forearm in one, and tensor 
fasciae latae (TFL) in one patient. Three patients received heparin intraoperatively: one 
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because of femorodorsal bypass with an autologous vein to enhance blood circulation to the 
flap, another because blood appeared to clot in the operation area, and the third after removal 
of an intraoperative arterial thrombus with a fogarty catheter. For the statistical analysis, this 
group was divided into two according to previous trauma: 1) patients with recent trauma (< 3 
months; four patients), and 2) patients with older trauma (> 3 months) or chronic ulcer (four 
patients). 
 
The cancer group (study III) 
 
The cancer group consisted of seven patients undergoing elective reconstructive 
microsurgery. Five of them had oral or pharyngeal cancers: one of them had a recurrent 
cancer in the tongue (the first tumour had been removed 5 yr earlier), one in the tonsillae, and 
one in the floor of the mouth; two had a cancer in the larynx, one of them with metastases in 
the neck. The remaining two had sarcoma in the extremity: one a synovial sarcoma in the 
elbow, and the other a malignant fibrous histiocytoma (MFH) in the lower leg. One patient 
with larynx cancer had received preoperative irradiation within the previous 12 months and 
had undergone two operations for lung cancer, 4 and 1 yr earlier. The other patient with 
larynx cancer had been operated on for stomach cancer 8 yr earlier. Microsurgical 
reconstruction in all the head and neck cancer patients was performed with a radial forearm 
flap. The patient with a synovial sarcoma in the elbow was treated, at his own request to 
retain his hand, by amputation of the humerus and replantation of the remnant forearm to the 
stump of the arm. The patient with MFH in the lower leg received a latissimus dorsi flap to 
cover the defect. Vein grafts were used in two patients to reconstruct the radial artery; in one 
of these patients a thrombus formed intraoperatively at the proximal arteriovenous 
anastomosis and required resection and reanastomosing.  
 
The vessel sample group (study I) 
 
The failed vessel samples for immunohistochemical study were gathered from 12 patients 
undergoing elective free flap surgery: nine for late breast reconstruction with a TRAM flap, 
two for immediate reconstruction due to oropharyngeal cancer with a radial forearm flap, and 
one for reconstruction due to a 2-week-old instabile lower leg fracture with a LD flap 
combined with scapular bone. One sample was also obtained from a digital artery of a patient 
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whose thumb and three other fingers were primarily replanted by the hand surgeons, but who 
developed thrombosis on the 1st postoperative day and was reoperated on by the plastic 
surgery team. 
 
All of the patients except one were female, with a mean age of 51 (range 34 - 75) yr. Three 
patients received medication for hypertension. One patient, who had been operated on for 
breast cancer with axillar metastases 3 yr earlier, was treated with tamoxifen. The patient with 
cancer of the larynx had been surgically treated for stomach cancer 8 yr earlier. Four of the 
patients were current smokers. During the primary operations, vein grafts were used in four 
patients: in two of the TRAM patients and in both cancer patients.  
 
4.1.2. Blood sampling and analysis (Studies I, II and III) 
 
Four blood samples for plasma markers were routinely taken from each patient at the 
beginning of the operation before the induction of anaesthesia (B), at 2 h (± 30 min) after the 
start of the operation (2h), at the end (± 1h) (E), and at 24 h (± 6h) after completion of the 
operation (24h). Additional samples were taken, if needed, in the event of intraoperative 
thrombosis (T) or postoperative thrombosis requiring reoperation (R). Free flowing blood was 
collected via a clean venipuncture or through an arterial cannula (Viggo® AB, Helsingborg, 
Sweden). The first 3 ml or 6 ml, respectively, were discarded. The blood was collected in 
plastic tubes containing 3.8% sodium citrate (9:1); approtinin (0.2 TIU/ml) was added for D-
dimer, and prostaglandin E1 (0.9 µM) and theophylline (10 mM) for PAI-1 (Kluft and 
Verheijen 1990). Within 1 h of the collection, samples were centrifuged at 1800 G (+22° C) 
for 10 min, except for the PAI-1 samples, which were centrifuged for 30 min (+4° C). The 
plasma was then separated, divided into aliquots, and stored at -70° C until analysed. Routine 
blood cell counts and C-reactive protein (CRP) determinations to detect 
infection/inflammation were conducted before and after surgery (CRP, immunochemical 
method; Orion Diagnostica, Espoo, Finland). 
 
The plasma markers were analysed within 6 months. Fibrinogen (reference value < 4 g/l) was 
determined by the functional method of Clauss. Enzyme-linked immunosorbent assays were 
used to determine TAT (< 4.1 µg/l), F1+2 (< 1.1 nmol/l), D-dimer (< 400 ng/ml), tPA (< 20 
ng/ml), and PAI-1 (< 43 ng/ml) (Enzygnost TAT micro and Enzygnost F1+2 micro, 
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Behringwerke AG, Marburg, Germany; Asserachrom D-di, Diagnostica Stago, Asnieres-sur-
Seine, France; TintElize tPA and TintElize PAI-1, Biopool, Umeå, Sweden, respectively). 
F1+2 and PAI activities (< 40 U/ml) [Spectrolyse (pL) PAI, Biopool] were measured only in 
patients with intra- or postoperative thrombosis. The functional concentration of dalteparin 
was determined by photometric anti-factor Xa assay (Coatest LMW Heparin/Heparin; Kabi 
Diagnostica, Mölndal, Sweden). 
 
4.1.3. Vessel samples and their histopathological and 
immunohistochemical analysis (Study I) 
 
Vessel samples and associated clinical manifestations  
 
A total of 17 vessel samples were obtained from 13 patients. The majority (14/17) of the 
samples were taken during primary surgery, and in half of them the clinical manifestation at 
operation was obvious thrombosis. In the other cases the anastomoses were defined as non-
functioning, or as having poor flow or too sharp a pulse during primary surgery. Three of the 
vessel samples were resected at reoperations when an obvious occlusion was present. The 
samples consisted mainly of the arterial anastomosis region, and in some cases the adjacent 
piece of vessel was also resected. Since, however, two samples were obtained from 
thrombosed arterialised vein grafts, one sample of a venous thrombus was included for 
comparison. 
 
Sample preparation 
 
After resection, the anastomosis or adjacent piece of vessel was fixed in formalin. Later, the 
stitches were removed from the formalin-fixed anastomoses under light microscope. If the 
samples were long, they were transversely cut into 2-8 mm slices and then embedded in 
paraffin. During the stitch removing procedure the overall morphology and histopathology of 
the vessels and adjacent thrombi were primarily evaluated.  
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Immunohistochemistry 
 
Immunohistochemical markers 
 
The immunohistochemical markers used were: CD31 (PECAM-1, platelet-endothelial cell 
adhesion molecule; DAKO A/S, Glostrup, Denmark), CD42b (glycoprotein=GP 1b α; 
Novocastra Laboratories Ltd., Newcastle upon Tyne, UK) and fibrin (fibrin II, T2G1; 
Accurate Chemical & Scientific Corp., Westbury, NY, USA) (Bini et al. 1989). 
 
Staining procedure 
 
In the prepared transverse sections immunohistochemical staining was carried out by standard 
methods (Hsu et al. 1981). The paraffin-embedded sections were deparaffinised and then the 
slides used for the CD42b and fibrin stainings were pretreated with citric acid solution in a 
microwave oven to enhance the staining intensity (von Boguslawski 1994). To enhance the 
staining intensity with the CD31 antibodies, the deparaffinised sections were treated with 
0.4% pepsin solution in 1 M HCl (Sigma No P-7000) for 1 h at 37 ºC before the H
2
O
2
 
blocking. After rinsing in PBS, the deparaffinised sections were incubated with blocking 
serum (10% horse serum in PBS) for 15 min. Thereafter, the sections were incubated 
overnight with primary monoclonal antibodies at optimal dilution (CD31 1:100, CD42b 1:500 
and Fibrin 1 1:500) in humid atmosphere at room temperature. After the sections had been 
rinsed in PBS, the avidin-biotin complex (ABC) detection method was used (Vectastain Elite 
ABC- Kit, Vector Laboratories Inc., Burlingame, CA). Finally, the sections were developed in 
3-amino-9-ethylcarbazole (Sigma No A-5754) solution (0.2 mg/ml in 0.05 M acetate buffer 
containing 0.03% H
2
O
2
) and counterstained with Mayer´s haematoxylin. 
 
Evaluation of immunoreactivities 
 
Immunoreactivities were visually assessed by two experienced observers, who evaluated the 
vessel structures and amount of stained cells in the studied areas. The immunoreaction was 
scored: negative (-), or slightly (+), moderately (++) or strongly (+++) positive.   
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4.1.4. Statistics (Studies I, II and III) 
 
The statistical analysis in the studies on activation of blood coagulation and fibrinolysis 
during microsurgical reconstructions was made by using SigmaStat®, version 2.0 for 
Windows® 95, Jandel statistical software. The Spearman Rank Order Correlation test was 
used when both variables were continuous. In comparisons of two groups, the Fisher Exact 
Test, paired t-test or Mann-Whitney Rank Sum Test was used, as appropriate. The Friedman 
Repeated Measures Analysis of Variance on Ranks was applied to compare coagulation and 
fibrinolysis parameters at different time intervals within groups. The values are expressed as 
mean ± standard error of mean (SE) or as mean (range), unless otherwise indicated.  
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4.2. ANIMALS AND METHODS; EXPERIMENTAL PART - 
Study IV 
 
4.2.1. Animals and thrombosis models in experiments I-III 
 
Experiments I-III 
 
We studied the capacity of heparin proteoglycans (HEP-PG) to inhibit both early and late 
thrombus formation in rat common femoral arteries, and we measured it semiquantitatively 
with scanning electron microscopy (SEM) and quatitatively with Indium 111-labelled 
platelets. We thus set up three different experiments in a total number of 87 rats as follows:     
Experiment I: Study of early (10 min) thrombus formation in three thrombosis models 
analysed by SEM. A total of 45 samples, 15 in each thrombosis model, five in each irrigation 
solution group, were analysed. This procedure was a pilot study to find the thrombosis model 
best reproduceable and most suitable for quantification. 
Experiment II: Assessment of early (10 min) thrombus formation on an anastomosis with 
Indium 111-labelled platelets. The platelet specific radioactivity was measured and translated 
into the number of attached platelets per vessel in 21 samples in the different irrigation 
solution groups. 
Experiment III: A 3-day follow-up study in the anastomosis model. The study comprised 21 
samples, of which 12, four in each of the irrigation solution groups, were analysed by SEM. 
 
Animals and operation technique 
 
Our animal models were male Brown Norwegian (BN/R1) rats (210-490 g) in all three 
experiments and, in addition, male rats of an inbred strain of WAG/RijHsd (270-390g) in 
experiment II. The animals were fed a regular rat chow diet, with water provided ad libitum. 
In experiment III the rats were individually caged during the follow-up period. Animal care, 
anaesthesia and the experimental protocol complied with the guidelines of the Helsinki 
University Central Hospital animal care committee. The rats were anaesthetised i.p. 0.10-0.15 
ml/kg with a mixed solution of fentanyl-fluanisone (Hypnorm, Jansen-Cielag, 
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Buckinghamshire, UK), midazolam (Dormicum, Roche, Basel, Switzerland) and sterile aqua 
(10 ml, 3 ml and 10 ml, respectively) according to approximated weight. After anaesthesia, 
the rats were weighed before the operation. During the operation additional doses of 
anaesthetic were given if required. The operations were performed with a clean, but not 
sterile, technique under an operating microscope (Wild M 651, Heerbrugg, Switzerland). 
Before the operation, the rats´ groins were shaved and thereafter a linear incision was made 
overlying the femoral vessels. The common femoral artery (diameter 0.7-1.0 mm) was 
dissected free and smaller branches were electrocauterised. A plastic sheet was placed under 
the artery to isolate it from surrounding structures. A standardised number of stitches was 
used in the different thrombosis models, the suture material being 10-0 nylon (non sterile 
microsutures for experimental surgery, B. Braun-SSC AG, Neuhausen, Switzerland). In 
experiment II, the contralateral femoral artery was dissected as on the other side but not 
opened. After completion of the dissection, the distal part was ligated with 9-0 Nylon 
(B.Braun-SSC AG, Emmenbruck, Switzerland), the vessel was then cut, and a 24-G 
intravascular neonatal Neoflon cannula (BOC Ohmeda AB, Helsingborg, Sweden) was 
inserted proximally for blood sampling and injection of Indium 111-labelled platelets. In all 
experiments, the vascular clamps were released and bleeding time was recorded. Bleeding 
time was measured as the time elapsing between release of the microvascular double clamp 
(restoration of blood flow) and cessation of bleeding from the sutured 
arteriotomy/anastomosis. Patency was tested at 10 min in all experiments, and in experiment 
III repeatedly up to 3 days postoperatively. In experiment III, the skin incision was sutured 
after a patency test performed at 60 min. At 24 h the animals were again anaesthetised, the  
wound was opened and a patency test was performed and the wound closed. After the final 
patency test (10 min in experiments I and II, and 3 days postoperatively in experiment III) 
vascular clamps were again inserted on each side of the injured area and a piece (3-5 mm) of 
the vessel was dissected, either for SEM or measurement of radioactivity, and flushed gently 
with normal saline to release the remaining blood from the lumen. At the end of the 
procedure, while the animals were still anaesthetised, a blood sample was taken by cardiac 
puncture for measurement of thrombin time (experiment I). A lethal dose of barbiturate (1 ml, 
Mebunat

, Orion, Espoo, Finland) was then given by cardiac puncture (experiments I and III) 
or via intra-arterial cannula (experiment II). All surgical procedures were performed by the 
same microsurgeon. 
 
 45 
Thrombosis models 
 
We started the pilot studies in the first experiment by using the model of Davidson et al. 
(thrombosis model 1, TM 1; Davidson et al. 1990), which we modified by not applying stasis. 
The thrombogenic injury was made as follows: the loose adventitia on the left common 
femoral artery was removed from the area of intended injury and a bulldog clamp was placed 
on the vessel for 2 min to create a crush injury. Next, a microvascular double clamp was 
placed on the vessel, and a transverse arteriotomy involving approximately one-half of the 
circumference was made between the two clamps. The intima proximal to the arteriotomy on 
the anterior side (=arteriotomy side) of the vessel was then scratched with a 5-mm tapered 
microsurgical needle (B. Braun-SSC AG, Emmenbruck, Switzerland) through the arteriotomy 
site to create a subendothelial injury (approximately 20 scratches). The arteriotomy was 
closed with 3-5 stitches.   
 
The second model (thrombosis model 2, TM 2) in the pilot studies was that described by 
Barker et al. consisting of arteriotomy and inversion of the full thickness of the vessel wall 
into the lumen (Barker et al. 1992). We modified this model by enlargening the flap from one-
third to one-half and by reversing the inverted flap site. The thrombogenic injury was made as 
follows: a microvascular double clamp was placed on the vessel and a transverse arteriotomy 
involving approximately one half of the circumference was made on the anterior side.  Three 
to five stitches were placed in a manner that inverted a full thickness of the distal vessel wall 
into the lumen and thus enabled all layers of the cut vessel end to confront circulating blood.  
 
The third model used in the first experiment was an ordinary end-to-end anastomosis (study 
IV). This model was chosen as the basic, physiological model for the second and third 
experiments. The thrombogenic injury was made as follows: a microvascular double clamp 
was placed on the artery, which was then transversely cut with microscissors. No adventitial 
circumcision was made at the vessel ends and only some of the excess loose hanging 
periadventitial tissue was removed. A regular anastomosis was performed with 8-10 stitches. 
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Irrigation solutions and thrombin time 
 
Three different irrigation solutions in a volume of 0.2 ml were used in all experiments in a n 
open manner. The solutions included normal saline (saline group, controls), heparinised 
normal saline (unfractionated heparin, Heparin Lövens, Ballerup, Denmark, MW 15 kD, 1 
mg/ml) (HEP group) (Cox et al. 1992) and heparin-proteoglycans (HEP-PG, MW 750 kD, 10 
ug/ml) (HEP-PG group). The remaining blood was flushed away from the vessel lumen with 
normal saline. Any exess saline remaining around and inside the vessel was dried before 
either HEP-PG, UFH or saline was applied into the lumen at the site of arteriotomy; half of 
the solution was given at the beginning of suturing and the other half before the last two 
stiches were tied. HEP-PG was obtained as a soluble fraction of stimulated (compound 48/80) 
rat serosal mast cells, as previously described (Lassila et al. 1997). To evaluate the systemic 
effect of the irrigation solutions, thrombin time was measured in the anastomosis model at 10 
min in experiment I. 100 µl of citrated plasma was incubated with 0.7 U of Test Thrombin 
Reagent (Behring Diagnostics GmbH, Marburg, Germany) according to the manufacturer´s 
instructions. 
 
4.2.2. Methods for thrombosis evaluation 
 
Patency testing (experiments I, II and III) 
 
To evaluate the occurrence of occlusive thrombi, patency was tested at 10 min in all 
experiments (I-III), and in experiment III repeatedly at 30 min, 60 min, 24 h and 3 days 
postoperatively. The patency test (distal milking test) was performed using two pairs of 
microforceps, the first clamping and occluding the vessel just distal to the sutured 
arteriotomy/anastomosis and the other emptying the blood more distally over a short distance. 
The first pair of forceps was then opened and patency assessed (Wieslander et al. 1990). The 
criterion of patency (P) was rapid or good refilling and that of absent patency (T, thrombosis) 
no refilling. An additional definition, between P and T, was markedly reduced flow (Rf). 
Vessels with markedly reduced flow or no refilling, but which were still distally dilated with 
pulsewave (thought to represent distal perfusion via collaterals), were separately defined by * 
(Rf*, and T*, respectively). 
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Scanning electron micrographs (SEM) (experiments I and III) 
    
For the semiquantitative analysis by SEM, the dissected piece of vessel was carefully opened 
longitudinally with microscissors, placed on a plastic sheet and sutured  with 2-4 stitches to 
keep the tissue piece flat for fixation. The vessel-on-plastic was put into a polypropylene tube 
containing 2.5% glutaraldehyde for 2 h for fixation at 22 °C. After fixation the sample was 
rinsed with and placed in PBS to be processed routinely for SEM (Lassila et al. 1997). The 
2.5% glutaraldehyde-fixed samples were dehydrated, critical-point dried with CO
2
, sputter-
coated with platinum, and viewed by SEM (Jeol JSEM-820 scanning electron microscope, 
Tokyo, Japan) at the Institute of Biotechnology, Electron Microscopy, University of Helsinki. 
The electronmicroscopist did not know what irrigation solution had been used. In experiment 
I, two scanning electron micrographs were obtained of each sample at standard 
magnifications of x 45 and x 300 and preanalysed for severity of thrombotic response. The 
pictures were later grouped and re-examined by two independent observers, and the 
intraluminal thrombotic material was quantified as -/+ (clean or minimal amounts), + (small 
amounts), ++ (moderate amounts) or +++ (large amounts). In experiment III, one picture was 
taken of each sample at a magnification of x 60 to optimally cover the whole anastomotic 
area. 
 
Measurement of Indium 111-labelled platelets (experiment II) 
 
Platelet preparation and labelling  
 
In experiment II, the thrombotic response was quantified by using Indium 111-labelled 
platelets. The labelled platelets were prepared by collecting samples from anaesthetised rats 
of the same strain as those on which the experiment was performed (either BN/R1 or 
WAG/RijHsd). The blood was collected into polypropylene tubes containing 1/10 volume of 
acidic citrated dextrose (ACD) anticoagulant and repeatedly centrifuged (1900 rpm, at 22 °C) 
for 15-30 s four times. Between each spin the platelet-rich plasma (PRP) layer was collected 
and anticoagulant was added as described by Catalfamo and Dodds (Catalfamo adn Dodds 
1989). 10 vol of the pooled PRP was added in 1 vol of ACD; the platelets were washed twice 
and resuspended in MTS buffer (NaCl 8 mg, KCl 0.2mg, MgCl
2  
x 6 H
2
O 0.43 mg, glucose 
1.1 mg, acidic citrate x H
2
O 1.34 mg, Na OH 0.36 mg, per 1 ml H
2
O) at normal pH. Indium 
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111-label (100 µCi) was added to the platelet suspension and incubated for 5 min. To capture 
unbound Indium 111-label, platelet-poor plasma (PPP) was added, and the suspension was 
centrifuged at 2000 rpm for 5 min. Finally, the platelet pellet was resuspended in 0.9% NaCl 
to obtain a platelet number between 400 and 600 x 10
6
/ml for injection.  
 
Blood sampling and injection of Indium 111-labelled platelets  
 
Blood samples for platelet count and thrombin time were collected via the inserted cannula on 
the arteria femoralis into plastic syringes containing EDTA and 110 mM sodium citrate, 
respectively. The vessel surface on the opposite femoral artery was treated with the irrigation 
solution, and the anastomosis was completed. Thereafter the double clamp was released, and 
after 15 s Indium 111-labelled platelets (200-300 x 106 in 0.5 ml) were infused slowly (within 
40-55 s) via the cannula. After 10 min patency was tested, the anastomosis was resected, and 
two blood samples (0.5 ml and 1.0 ml) were taken for platelet count and for measurement of 
radioactivity in the blood. 
 
Vessel samples and measurement of radioactivity 
 
The anastomosed tissue sample was kept unopened and put into a polypropylene tube 
containing 2.5% glutaraldehyde. The retained radioactivity was measured (LKP, Wallac 1272 
clinigamma, Turku, Finland) together with the blood samples to assess platelet-related Indium 
111 activity. The number of platelets deposited on the vessel was calculated from the activity 
of the blood and its platelet number. 
 
4.2.3. Statistics 
 
The variability of the results between the three different groups was statistically tested with 
ANOVA using Fisher’s exact t-test.
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5. RESULTS 
 
5.1. Activation of coagulation and fibrinolysis in free flap surgery 
- association with flap failure (Studies I, II and III) 
 
Outcome of the patients and intra- and postoperative thrombotic events  
 
The TRAM group (n=9) consisted of six patients with obvious or suspected intraoperative 
thrombosis, and of three patients without thrombosis, see Table 3.  Five of the patients with 
thrombotic events are discussed in study I; the data on the other patients in the TRAM group 
are unpublished. One of the patients with intraoperative thrombosis requiring resection of the 
vessel and replacement by vein graft, the oldest patient in the TRAM group (age 74), 
underwent two reoperations, on the 3rd and 7th postoperative days, because the graft 
occluded. The final outcome was good. The outcome was also uneventful for all the other 
patients except one in whom a thrombus formed during primary surgery and small edge 
necrosis developed some months later. 
 
In the lower extremity trauma group (n=8), comprising patients with both recent and old 
trauma in the lower extremities, only one of the patients with old trauma had an event of 
intraoperative thrombosis (Table 3). Hovever, three patients had an event of postoperative 
thrombosis requiring reoperation on the same day as primary surgery; the outcome was good 
in two of them, both with recent trauma. The third patient, the one with ASO and LED, had a 
flap failure on the 8th postoperative day, and her lower leg had to be amputated. All the other 
patients in this group had a good outcome. The patient data are published in study II. 
 
In the cancer group, two thrombotic events (one intraoperative and one postoperative) 
occurred (Table 3), but no flaps were lost. In the patient with metastatic larynx cancer, in 
whom an autogenous vein graft was used to reconstruct the radial artery, an intraoperative 
thrombus formed at the proximal arteriovenous anastomosis in the forearm, making resection 
and reanastomosis necessary. The other patient, who was operated on for an epidermoid 
cancer in the floor of the mouth, had to undergo reoperation on the 8th postoperative day 
because of necrosis in the tongue due to thrombosis in the arteria lingualis, and the tongue had 
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to be removed. The vessels to the radial forearm flap nevertheless functioned well. The cancer 
group is presented in study III.  
 
Preoperative hypercoagulable state - baseline values of the plasma markers  
 
The baseline values of the plasma markers in the various groups are shown in Table 4 and in 
Figures 2 and 3. F1+2 was measured only in patients with thrombotic complications.  
     
     
TABLE 4. Marker levels at the beginning of the operation in groups I-III. Group I = TRAM patients 
(n=9), group II = patients with lower extremity trauma (n=8), group III = cancer patients (n=7). The 
values are mean (range). 
     
     
MARKER GROUP I GROUP II GROUP III REFERENCE VALUES 
     
Fibrinogen 3.1 (2.4-4.2) 4.6 (2.7-5.6) 4.0 (2.5-5.6) 2-4 g/l  
     
TAT 3.8 (1.7-9.0) 5.7 (1.3-16.0) 6.8 (1.2-19.3) 1.0-4.1 µg/l 
     
F1+2 1.3 (0.8-1.7) 1.2 (0.9-1.5) 1.9 (1.8-2.0) 0.4-1.1 nmol/l 
     
D-dimer 161 (57-377) 539 (307-1211) 383 (40-835) <400 ng/ml 
     
tPA 4.5 (2.8-6.7) 8.4 (3.4-12.2) 8.2 (5.0-13.1) 1-20 ng/ml 
     
PAI-1  9.0 (3.2-32.9) 11.1 (3.5-23.2) 9.4 (1.6-20.6) 4-43 ng/ml 
     
     
TAT indicates thrombin-antithrombin complex, F1+2 prothrombin fragment 1+2, tPA tissue-type 
plasminogen activator, and PAI-1 plasminogen activator inhibitor-1. F1+2 was measured only from 
patients with thrombotic events. 
     
     
In the TRAM group, the baseline values of most of the patients were within normal limits. 
The patient who required two reoperations, on the 3rd and 7th postoperative days, had a 
clearly elevated baseline F1+2 (1.7 nmol/l). TAT and F1+2  were slightly elevated in two 
other TRAM patients, both with intraoperative thrombotic events.   
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The patients with lower extremity trauma had normal baseline levels of fibrinogen, TAT and 
F1+2, but two of them (one with recent trauma and the other with ASO+LED), both of whom 
underwent reoperation later on the same day, had slightly elevated F1+2. The patient with 
intraoperative thrombosis already showed signs of thrombin generation (F1+2 1.5 nmol/l) 
before surgery. When patients with recent trauma were compared with those having older or 
no trauma within group II, it was found that D-dimer levels were clearly elevated (747 ± 175 
vs 331 ± 8 ng/ml, p = 0.03) in the patients with recent trauma.  
 
A preoperative hypercoagulable state was seen in four of the cancer patients. Fibrinogen and 
TAT values were above the reference limits in three, and D-dimer values in two of the 
patients. The thrombotic complications occurred in one patient who had several elevated 
values, i.e. fibrinogen, TAT, F1+2 and D-dimer (postoperative event), and in another patient 
with elevated TAT and F1+2 values (intraoperative event).  
 
The time course of coagulation and fibrinolytic parameters  
 
The time course of the coagulation and fibrinolytic parameters in the three groups is shown in 
Figures 2 and 3. Some of the plasma markers followed a general pattern during the operation. 
Fibrinogen significantly declined from the beginning to the end of the operation, returning to 
baseline level on the 1st postoperative day in all patients within the groups.  
 
The coagulation markers, TAT and F1+2, varied considerably during the operation within the 
groups. TAT values increased markedly towards the end of the operation in most of the 
TRAM patients without thrombosis, but no increase was seen in the subgroup with 
thrombosis. Of interest here was the 2-5-fold increase in TAT and F1+2 at obvious 
intraoperative thrombosis in two patients, one of them showing an over 10-fold increase in 
TAT at 24 h (36 µg/l) and subsequent edge necrosis 2 months later. The TRAM patient who 
required two reoperations, on the 3rd and 7th postoperative days, showed over 2-fold 
enhanced coagulation activity at the time of postoperative thrombosis. In the lower extremity 
trauma group three patients showed an up to 5-fold increase in TAT and F1+2 values at the 
end of the operation, and all three were reoperated on the same day due to postoperative 
thrombosis; one of them required also a second reoperation, a lower leg amputation, due to 
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necrotic flap on the 8th postoperative day (the data on the first reoperation of the patient with 
two reoperations are not shown in Figures 2 and 3). In the lower extremity trauma patient 
with intraoperative thrombosis, thrombin generation persisted at 24 h (F1+2 2.6 nmol/l). In 
the cancer group, TAT values consistently increased by as much as 6-fold at the end of the 
operation, returning to normal at 24 h in all patients, except the one with postoperative 
thrombosis.  
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Figure 2. Time course of fibrinogen (FG), thrombin-antithrombin III complex (TAT) and 
prothrombin fragment 1+2 (F1+2) during free flap transfers in groups I-III. Group I = patients 
undergoing late breast reconstruction with a transversus rectus abdominis musculocutaneous 
(TRAM) flap (black triangles indicate patients with thrombotic complications, and open 
triangles patients with uncomplicated operations), Group II = patients with lower extremity 
trauma or chronic ulcer in lower extremitites ( black circles indicate patients with recent 
trauma, and open circles patients with older trauma or chronic ulcer), Group III = patients 
with oropharyngeal cancer or cancer in the extremitites (black rhomboids  indicate the patient 
with postoperative thrombosis, and open rhomboids the patient with intraoperative 
thrombosis). B = at the beginning of the operation, 2h = at 2 h from the beginning, T1 = at 
first intraoperative thrombosis, T2 = at second intraoperative thrombosis, E = at the end of the 
operation, 24h = at 24 h after completion of the operation, R1 = at first reoperation, R2 = at 
second reoperation. 
 
D-dimer showed a general decrease during the operation in the TRAM patients with 
intraoperative thrombosis and in all patients in the lower extremity trauma group except two 
with recent trauma, whose levels remained elevated during primary surgery and at 
postoperative thrombosis and who required reoperation on the same day. Activation of 
fibrinolysis with increased D-dimer values at 24 h occurred in all the TRAM patients without 
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thrombosis, but in only one patient with intraoperative thrombosis. Also, the TRAM patient 
who was reoperated on twice showed activation of fibrinolysis at the time of reoperations. 
Only one patient with lower extremity trauma showed a clear increase in the values at 24 h 
and at the time of the second reoperation. Interestingly, in the cancer group, following 
activation of coagulation, fibrinolysis was clearly stimulated at 24 h, as shown by the 2-3-
fold, maximally even 10-fold, increase in D-dimer values.  
 
The fibrinolytic markers tPA and PAI-1 ag were within normal limits at all times in most of 
the patients. In two TRAM patients, PAI-1 antigen values increased 2-6-fold at the time of the 
second intraoperative obvious thrombosis; one of them also had a 2-fold increase in PAI-1 
activity (data not shown). One patient with lower extremity trauma showed a clear increase in 
tPA values at the time of the second reoperation due to a necrotic flap. Two other trauma 
patients with postoperative thrombosis had a 2-2.5-fold increase in PAI-1 antigen levels at the 
time of reoperation, one of them having a 5-fold increase in PAI-1 activity as well. Of special 
interest in the cancer group was the increase in tPA and PAI-1 in the two patients who 
developed thrombosis, whereas in the patients without thrombotic complications the 
fibrinolytic enzymes remained quite stable.  
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Figure 3. Time course of D-dimer, tissue-type plasminogen ativator (tPA) and plasminogen 
activator inhibitor-1 (PAI-1) antigens during free flap transfers in groups I-III. Group I = 
patients undergoing late breast reconstruction with a transversus rectus abdominis 
musculocutaneous (TRAM) flap (black triangles indicate patients with thrombotic 
complications and open triangles patients with uncomplicated operations), Group II = patients 
with lower extremity trauma or chronic ulcer in lower extremitites ( black circles indicate 
patients with recent trauma and open circles patients with older trauma or chronic ulcer), 
Group III = patients with oropharyngeal cancer or cancer in the extremitites (black rhomboids 
indicate the patient with postoperative thrombosis and open rhomboids the patient with 
intraoperative thrombosis). B = at the beginning of the operation, 2h = at 2 h from the 
beginning, T1 = at first intraoperative thrombosis, T2 = at second intraoperative thrombosis, 
E = at the end of the operation, 24h = at 24 h after completion of the operation, R1 = at first 
reoperation, R2 = at second reoperation. 
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Thrombotic events and their correlation with operative factors and plasma 
markers 
 
When the baseline values of the plasma markers in the combined group of patients were first 
scrutinised, most of the markers were on the same level in patients with (n=8) and without 
(n=16) intraoperative thrombotic events. Only the values of tPA were somewhat elevated in 
patients without intraoperative thrombosis as compared with those in patients with 
thrombosis, see Table 5. 
    
    
TABLE 5. Marker levels at the beginning of the operation in patients with intraoperative thrombotic events 
(n=8) compared with patients without intraoperative local thrombosis (n=16) in combined group I-III. Group I 
= TRAM patients, group II = patients with lower extremity trauma, group III = cancer patients. 
    
    
MARKER THROMBOSIS + THROMBOSIS - p Value 
    
Fibrinogen (g/l) 3.2 +/- 0.2 4.2 +/- 0.3 ns 
    
TAT (µg/l) 6.6 +/- 2.3 4.8 +/- 1.2 ns 
    
D-dimer (ng/ml) 228 +/- 46 413 +/- 85 ns 
    
tPA (ng/ml)   5.1 +/- 0.6 7.8 +/- 0.8 0.04 
    
PAI-1 (ng/ml) 9.4 +/- 3.9 10.0 +/- 1.6 ns 
    
    
 
When only the TRAM patients with intraoperative thrombosis (six out of nine patients) were 
compared with patients without thrombosis (three out of nine patients) it was found that the 
former had a longer operation time and ischaemia time, more bleeding, and received a greater 
amount of blood during the operation, see Table 6. They also had higher D-dimer levels at the 
end of the operation, and showed persistent thrombin generation (TAT) and fibrinolysis 
activation (PAI-1 ag) at 24 h.  
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TABLE 6. Significant differences in variables within TRAM patients with (n=6) or without (n=3) 
thrombosis. The values are means +/- SE. 
    
    
VARIABLE THROMBOSIS + THROMBOSIS - p Value 
    
Operation time (min) 481 +/- 22 308 +/- 17 0.02 
Ischaemia time (min) 114 +/- 19 48 +/- 2 0.02 
Intraoperative bleeding (ml) 1350 +/- 240 450 +/- 50 0.02 
Intraoperative blood transfusion (units) 3.3 +/- 0.7 0.3 +/- 0.3 0.02 
    
D-dimer E (obv.art.thrombus) 225 +/- 71 92 +/- 11 0.02 
TAT 24h (obv.art.thrombus) 15.7 +/- 10.1 2.8 +/- 0.2 0.02 
PAI-1 24h (thrombus) 11.9 +/- 2.8 4.8 +/- 0.4 0.02 
    
    
Obv.art.thrombus = patients with obvious arterial thrombus only (three out of nine patients).  
Thrombus= patients with both obvious and suspected arterial and venous thrombi intraoperatively 
(six out of nine patients). TAT indicates thrombin-antithrombin III complex, PAI-1 plasminogen 
activator inhibitor-1. E, 24h = sample taken at the end of the operation or at 24 h. 
    
    
 
In the lower extremity trauma group, the patients with postoperative thrombosis requiring 
reoperation (three out of eight patients) had a greater amount of bleeding and thus received 
more blood during the operation than did those who were not reoperated on (five out of eight 
patients), see Table 7. The patients who required reoperation had higher fibrinogen values at 
the baseline, and higher PAI-1 ag values were detected at the end of the operation. Also, D-
dimer levels were 2-fold higher at 24 h in the patients undergoing reoperation. PAI-1 activity, 
which was measured only in patients with thrombosis or reoperation, correlated positively 
with PAI-1 antigen (data not shown). 
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TABLE 7. Significant differences in variables in lower extremity trauma patients who were reoperated 
on (n=3) compared with patients who did not undergo reoperation (n=5). The values are means +/- 
SE. 
    
    
VARIABLE REOPERATION + REOPERATION - p Value 
    
Intraoperative bleeding (ml) 2000 +/- 681 340 +/- 19 0.04 
Intraoperative blood transfusion (units) 4.0 +/- 0.0 0.4 +/- 0.2 0.04 
    
Fibrinogen B 5.5 +/- 0.1 4.0 +/- 0.3 0.04 
Fibrinogen 2h 4.3 +/- 0.4 2.5 +/- 0.2 0.04 
PAI-1 ag E 11.5 +/- 3.2 5.8 +/- 0.7 0.04 
D-dimer 24h 875 +/- 80 400 +/- 71 0.04 
    
    
Three out of eight patients underwent reoperation; all three on the same day as primary surgery, and 
one of them again on the 8th postoperative day. PAI-1 indicates plasminogen activator inhibitor-1. B, 
2h, E, 24h = sample taken at the beginning of the operation, at 2 h, at the end of the operation, or at 
24 h. 
    
    
 
Differences in the marker levels between patients who were judged to need intraoperative 
heparin and those who did not, differentiating patients in the TRAM group and lower 
extremity trauma group, are shown in Table 8. There were no significant correlations between 
the occurrence of intraoperative thrombosis or reoperation and age, weight, smoking, 
cardiovascular disease, preoperative use of NSAID, anti-factor Xa activity and use of vein 
graft in these small groups of patients. 
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TABLE 8. Significant differences in haemostatic and fibrinolytic variables between patients who  
received heparin intraoperatively and those who did not within groups I and II. Group I = TRAM 
patients (n=9), group II = patients with lower extremity trauma (n=8). The values are means +/- SE. 
    
    
GROUP & VARIABLE HEPARIN + HEPARIN - p Value 
    
Group I    
       D-dimer B 285 +/- 47 99 +/- 11 0.02 
       D-dimer 2h 197 +/- 41 75 +/- 13 0.02 
       TAT 2h 3.5 +/- 0.5 2.0 +/- 0.4 < 0.05 
    
Group II    
       tPA 2h 8.3 +/- 0.7 5.7 +/- 0.7 0.04 
       TAT 24h 4.2 +/- 0.6 2.6 +/- 0.2 0.04 
    
    
Three patients in both groups received heparin during the operation. Heparin was given between 2h 
and E samples. TAT indicates thrombin-antithrombin III complex and tPA tissue-type plasminogen 
activator. B, 2h, 24h = sample taken at the beginning of the operation, at 2 h or at 24 h. 
    
    
 
The overall correlation of plasma markers  
 
The patients with lower extremity trauma had markedly higher values for fibrinogen, D-dimer 
and tPA at the beginning of and during the operation than had the TRAM patients (Table 9). 
The cancer patients had notably higher values for tPA and fibrinogen at the beginning of the 
operation and higher values for D-dimer at the end of the operation, which persisted on the 1st 
postoperative day, than had the TRAM patients (Table 10). D-dimer values were also 
conspicuously elevated on the 1st postoperative day in cancer patients compared with patients 
with lower extremity trauma (1374 +/- 328 vs 578 +/- 100 ng/ml, p = 0.03).  
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TABLE 9. Significant differences in haemostatic and fibrinolytic markers between groups I and II. 
Group I = TRAM patients (n=9), group II= patients with lower extremity trauma (n=8).The values  
are means +/- SE. 
    
    
MARKER GROUP I GROUP II p Value 
    
    
Fibrinogen B 3.1 +/- 0.2 4.6 +/- 0.4 0.009 
Fibrinogen 2h 1.8 +/- 0.1 3.1 +/- 0.4 0.009 
Fibrinogen E 1.6 +/- 0.2 2.7 +/- 0.3 0.01 
    
D-dimer B 161 +/- 34 539 +/- 113 0.002 
D-dimer 2h 116 +/- 25 352 +/- 110 0.03 
D-dimer E 137 +/- 31 440 +/- 158 0.04 
    
tPA B 4.5 +/- 0.4 8.4 +/- 1.1 0.01 
tPA 2h 5.1 +/- 0.9 6.7 +/- 0.7 < 0.05 
    
    
tPA indicates tissue-type plasminogen activator. B, 2h, E = sample taken at the beginning of the 
operation, at 2 h, or at the end of the operation.  
    
    
    
    
TABLE 10. Significant differences in haemostatic and fibrinolytic markers between groups I and III. 
Group I = TRAM patients (n=9), group III = cancer patients (n=7). The values are means +/- SE. 
    
    
MARKER GROUP I GROUP III P Value 
    
Fibrinogen 2h 1.8 +/- 0.1 2.7 +/- 0.3 0.02 
    
D-dimer E 137 +/- 31 815 +/- 169 0.01 
D-dimer 24h 366 +/- 76 1375 +/- 328 0.008 
   	
   	
  
    
    
tPA indicates tissue-type plasminogen activator. B, 2h, E, 24h = sample taken at the beginning 
of the operation, at 2 h, at the end of the operation, or at 24 h. 
    
    
Pre- and postoperative values for haemoglobin (Hgb), haematocrit (Hct), platelets (plt), 
leukocytes (leuk) and CRP in the groups are shown in Figure 4. Several correlations between 
operative factors and plasma markers were detected at various time points in the combined 
group, as seen in Table 11. 
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Figure 4. Preoperative (preop) and postoperative (postop) values for haematocrit (Hct), 
platelets (plt), leukocytes (leuk) and CRP in patients with free flap transfers in groups I-III. 
Group I = patients undergoing late breast reconstruction with a transversus rectus abdominis 
musculocutaneous (TRAM) flap, Group II = patients with lower extremity trauma or chronic 
ulcer in lower extremitites, Group III = patients with oropharyngeal cancer or cancer in the 
extremities. * p < 0.05, ** p < 0.01, *** p < 0.001 as compared with the preoperative values. 
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TABLE 11. Correlations between plasma markers and operative factors in combined group I-III. Group I =  
TRAM patients (n=9), group II = lower extremity trauma patients (n=8), group III = cancer patients (n=7). 
   
   
 R p 
   
Haemoglobin and haematocrit vs fibrinogen B -0.44- -0.46 0.02-0.03 
Haematocrit vs TAT 24h 0.41 <0.05 
Haemoglobin and haematocrit vs tPA 24h 0.55-0.59 0.002-0.005 
Haemoglobin and haematocrit vs PAI-1 24h 0.55-0.64 0.006-0.0001 
   
Leukocytes vs tPA B and 24h 0.46-0.47 both 0.02 
Leukocytes vs PAI-1 B and 24h 0.52-0.58 <0.01-0.004 
Leukocytes vs D-dimer 24h 0.45 0.03 
   
Platelets vs TAT B 0.43 0.04 
   
CRP vs fibrinogen B and 24h 0.50-0.52 both 0.01 
CRP vs D-dimer 24h 0.47 0.02 
CRP vs PAI-1 24h 0.54 0.006 
   
Operation time vs TAT 24h 0.48 0.02 
Operation time vs tPA 24h 0.46 0.02 
Operation time vs PAI-1 E and 24h 0.43-0.54 0.03-0.008 
   
Tourniquet time vs TAT 24h 0.59 0.04 
   
Intraoperative bleeding vs TAT 24h 0.46 0.02 
Intraoperative bleeding vs tPA 24h 0.52 0.009 
Intraoperative bleeding vs PAI-1 E 0.64 <0.0001 
   
Postoperative blood transfusion vs tPA 24h 0.68 0.01 
   
   
 
The effect of LMWH (dalteparin) 
 
The level for systemic anticoagulation with dalteparin was assessed by anti -factor Xa activity 
before induction of anaesthesia. No significant correlations were found either in plasma 
markers at baseline when the patients who had received LMWH the previous evening were 
compared with those who had received it in the morning or in the patients with or without 
intraoperative thrombosis. In the TRAM group, anti-factor Xa activity ranged from 0.14 to 
0.55 U/ml in the patients who had received dalteparin 2500-5000 IU in the morning 2-3 h 
before induction of anaesthesia. In addition, anti-factor Xa activity was measured during the 
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operation in one patient who developed intraoperative venous thrombosis. The activity was 
lowest one, 0.14 U/ml, at the beginning of the operation; 8 h later, at the time of 
intraoperative thrombosis, it was undetectable (unpublished data). In the TRAM group, 
positive correlations existed between anti-factor Xa and tPA as well as PAI-1 levels at 2 h (r 
0.77-0.80).  
 
In patients with lower extremity trauma, anti-factor Xa activity ranged from 0.21 to 0.36 U/ml 
in the four patients who had received dalteparin 2500 IU in the morning 2-3 hours before 
induction of anaesthesia, one of them twice daily since the previous day. The remaining four 
patients, who had received dalteparin 2500 IU the previous evening, had anti-factor Xa 
activity levels of under 0.3 U/ml. One of these patients with non-valid anticoagulation levels 
received unfractionated heparin intraoperatively, since blood appeared to clot in the operation 
area and the anastomosis did not function optimally; another patient, the one with ASO and 
LED who received a vein graft, was also heparinised, but even so she developed a 
postoperative thrombosis and had to undergo reoperation some hours later.  
 
In the cancer group, the level of systemic anticoagulation ranged from < 0.04 (= undetectable) 
to 0.07 U/ml in the patients given dalteparin 2500-5000 IU the previous evening, and from 
0.26 to 0.38 U/ml in those given 2500 IU in the morning, 2-3 h earlier. The patient who 
developed intraoperative thrombosis had anti-factor Xa < 0.04, and the patient with 
postoperative thrombosis requiring reoperation 0.26 U/ml. 
 
5.2. Histopathology and immunohistochemistry of failed human 
anastomoses (Study I) 
 
Overall vessel morphology  
 
Evaluation of the overall morphology of the failed human anastomoses revealed technical 
problems in two of the anastomoses collected at TRAM reconstructions, a thrombus having 
formed adjacent to a constricting suture. An occlusive thrombus was present in 6/17 samples, 
and a smaller, non-occlusive thrombus in 4/17 samples. The other samples showed limited 
mural thrombosis only.   
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Immunohistochemistry  
 
The immunohistochemical analysis was targeted at the three main factors underlying 
thrombus formation: damaged endothelial cells, accumulation of platelets and accumulation 
of fibrin. We found colocalised loss of endothelial cells (CD 31) and accumulation of platelets 
(CD 42b) and mature fibrin at the failed anastomosis sites, see Table 12. Overall, the staining 
for platelets and fibrin correlated, the staining intensity for plateles being highest in the totally 
occluded samples. CD 31 (PECAM-1) was mainly used to verify the presence of endothelial 
cells, but since it is also expressed in platelets, it could recognise the adhered platelets as well 
(DeLisser et al 1993). A typical feature was the lack of PECAM-1-positive endothelial cells 
in the anastomosis area. These endothelium-deficient sites were mainly covered with 
moderate to large thrombi in which both platelets and fibrin were present. Of interest was the 
finding that, at the anastomoses with loss of endothelial cells, platelet-related PECAM-1 
staining, too, was lacking in the single layers of GP 1b α - positive platelets. However, mural 
and larger thrombi were positive for both PECAM-1 and CD 42b, detecting GP 1b α. 
Adjacent sections further from the anastomoses (2 mm - 3 cm), when available, revealed 
intact endothelial cells and only limited platelet and fibrin-associated staining.  
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TABLE 12. The expression of immunohistochemical markers at adjacent sides of 
anastomoses. 
Case #  CD 31 CD 42b Fibrin 
1. - / - ++ / +++ ++ / +++ 
2. - / - ++ / ++ + / + 
3. - / - + / - + / - 
4. - / - ++ / +++ ++ / ++ 
5. + / - ++ / ++ ++ / +++ 
6. - / +  +++ / +++ +++ / ++ 
7. a) + / +  ++ / + ++ / + 
b) - / - +++ / +++ +++ / +++ 
c) - +++ +++ 
8. - / - ++ / +++ ++ / ++ 
9. - / ++ ++ / + ++ / + 
10. a) - / - ++ / + + / + 
b) - / - ; - / - +++ / ++ ; +++ / ++ ++ / + ; ++ / ++ 
c) - / - ; - / - ++ / ++ ; +++ / ++ +++ / ++ ; +++ / ++ 
11. - / - + / ++  + / ++ 
12. - / - + / ++ ++ / +++ 
13. - / + + / ++ +++ / ++ 
The amount of markers attached the to vessel wall at adjacent sides of anastomoses 
( / ) scored as: - (not present), + (small amounts), ++ (moderate amounts), 
+++ (large amounts). 
)
CD 31 = PECAM-1 = platelet-endothelial cell adhesion molecule, used to detect both 
endothelial cells and platelets; CD 42b = GP 1b α, used to detect platelets. 
Case 7: samples a) and b) = resected anastomoses at intraoperative thromboses , c) 
thrombosed vessel proximal to b) anastomosis. Case 10: sample a) = anastomosis at 
primary operation, samples b) and c) = anastomoses at both ends of vein graft at 
reoperations; b) the whole vein graft + anastomoses thrombosed, c) anastomoses 
thrombosed, but a part of the vein graft open. 
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Histopathology 
 
Histopathological analysis of the failed anastomoses showed that inflammation of the vessel 
was a prominent feature at reoperations when the anastomosis was occluded. Inflammation 
was found in the two thrombosed vein grafts of the TRAM patient who underwent 
reoperations on the 3rd and 7th postoperative days, in the thrombosed venous anastomosis of 
the patient with tonsillar cancer at reoperation on the 3rd postoperative day and in the arterial 
sample from the patient with failed replantation of the mid-hand on the 1st postoperative day. 
In some of these vessels, the internal elastic lamina was discontinuous and fibrin was found, 
even in the smooth muscle cell layer extending into the media. In one of the TRAM patients, 
inflammatory cells had already been found at primary operation at the second thrombotic 
event (unpublished data).  
 
5.3. Local anti-thrombotic effect of HEP-PG (Study IV) 
 
Thrombin times and bleeding times 
 
In this experimental study we tested the local effect of HEP-PG in early (10 min) and late (3-
day) thrombus formation in rat common femoral arteries. We started the experiments with  
three different thrombosis models (TM), using SEM to evaluate early thrombus formation 
(experiment I). These models included scratching of the vessel wall (TM 1), arterial wall 
inversion (TM 2) and an ordinary microvascular anastomosis (TM 1 and TM 2 unpublished 
data). The anastomosis model was also used to quantify early thrombus formation with 
Indium 111-labelled platelets (experiment II) and to analyse late thrombus formation 
(experiment III). Three different irrigation solutions were employed locally at the site of 
vessel injury: saline (saline group, controls), unfractionated heparin (HEP group) and heparin-
proteoglycans (HEP-PG group). To exlude a systemic effect of the irrigation solutions we 
demonstrated that thrombin times were equal in each treatment group in the anastomosis 
model at 10 min  (mean, 
 
range): saline group 30.0 (27.8-31.0), HEP group 30.6 (27.6-35.3) 
and HEP-PG group 29.6 (28.2-31.3). In no experiment did bleeding from the sutured vessels 
differ significantly between the treatments. Bleeding times tended to be prolonged in the HEP 
group but did not markedly differ in the saline or HEP-PG groups, see Table 13 (TM 1 and 
TM 2 unpublished data).  
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TABLE 13. Bleeding times at 10 min in the thrombosis models.
Experiment & Model Saline group HEP group HEP-PG group
Experiment I
       TM1 52 (35-90) 72 (25-180) 35 (15-65)
       TM2 15 (0-30) 42 (10-75) 41 (5-150)
       Anastomosis 30 (10-60) 66 (20-100) 42 (15-80)
Experiment II (anastomosis) 34 (20-45) 45 (35-90) 49 (15-110)
Experiment III (anastomosis) 46 (15-120) 86 (30-225) 47 (15-100)
The values are means (ranges) in seconds. TM = thrombosis model.
 
 
Patency rates 
 
To test for the occurrence of occlusive thrombi, we tested patency in experiments I and II at 
10 min, and in experiment III repeatedly during a follow-up period of 3 days. Details of 
patency and blood flow characteristics in the three thrombosis models at the 10 min follow-up 
in experiment I are presented together with the results of the SEM analysis in Table 13 (TM 1 
and TM 2 unpublished data). In general, thrombotic occlusion and flow problems tended to 
occur in the saline group in TM 2 and anastomosis. The HEP and HEP-PG groups generally 
remained  patent but two animals in TM 1 showed somewhat compromised flow in the HEP-
PG group. The anastomosis model provided fairly uniform patency data in the HEP and HEP-
PG groups. In experiment II (Indium 111-labelling) patency at 10 min was 6/7 in the saline 
group, 6/6 in the HEP group and 6/7 in the HEP-PG group. In experiment III (3-day follow-
up) patency varied somewhat during the follow-up period (see Table 14), and on the 3rd 
postoperative day was as follows: 5/7 in the saline group, 6/7 in the HEP group and 7/7 in the 
HEP-PG group. 
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TABLE 14. Patencies of the anastomoses in experiment III with 3-day follow-up.
Group 10 min 30 min 60 min 24 hours 3 days
Saline Rat 1 T Rf T T T
Rat 2 P P P P P
Rat 3 P Rf T P T
Rats 4-7 P P P P P
HEP Rat 1 P P P P P
Rat 2 P Rf/P Rf/P P P
Rat 3 Rf Rf Rf Rf T
Rats 4-7 P P P P P
HEP-PG Rats 1-7 P P P P P
Rats 1-4 were further analysed by SEM.
Patencies: P = patent, rapid or good refilling; Rf = markedly reduced flow; T = thrombosed, no
refilling; Rf/P = vessels with markedly reduced flow at first but rapid or good refilling after repeated
testing.
 
 
SEM analysis 
 
Scanning electron microscopy was used in the semiquantitative analysis of early thrombus 
formation in the three thrombosis models. The results of SEM analysis regarding the extent of 
the thrombotic response in the three models are presented in Table 15 (TM1 and TM 2 
unpublished data). The quantification of thrombotic material (+/-, +, ++, +++, i.e. clean or 
minimal amounts, small amounts, moderate amounts, or large amounts) was graded from 1 to 
4.  
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TABLE 15. Results of SEM analysis and patency testing in the three thrombosis models (TM)
at 10 min.
Model Saline group HEP group HEP-PG group
TM 1 Rat 1 +++     (P) +        (P) ++       (T*)
Rat 2 +++     (P) ++      (P) +/-       (P)
Rat 3 +++     (P) +        (P) +         (P)
Rat 4 +         (P) ++      (P) +         (Rf*)
Rat 5 +         (P) +        (P) ++       (P)
TM 2 Rat 1 +         (P) +        (P) +         (P)
Rat 2 +++     (P) +        (P) +         (P)
Rat 3 +         (T) ++      (P) +/-       (P)
Rat 4 ++       (T*) +        (P) +         (P)
Rat 5 ++       (T*) +/-      (P) ++       (P)
Anastomosis Rat 1 ++       (P) ++      (P) ++       (P)
Rat 2 ++       (Rf) ++      (P) +         (P)
Rat 3 +         (P) +/-      (P) +/-       (P)
Rat 4 +++     (T/P) ++      (P) +         (P)
Rat 5 +++     (Rf/P) +++    (P) +/-       (P)
SEM: +/- (= 1) represents clean or minimal amounts, + (= 2) represents small amounts, ++ (=3)
represents moderate amounts, +++ (= 4) represents large amounts.
Patencies: P = patent, rapid or good refilling; Rf = markedly reduced flow; T = thrombosed, no
refilling; T/P, Rf/P = vessels with no refilling or markedly reduced flow at first but with rapid or
good refilling after repeated testing.
* = vessels that seemed to be patent (distally dilated with pulsewave) but with markedly reduced
flow or no reflow.
Within each group, the thrombotic response varied as follows: from clean or minimal to large 
amounts (1-4) in all saline-treated models and in the UFH-treated anastomosis model, from 
small to moderate amounts (2-3) in UFH-treated TM1, and from clean or minimal to moder-
ate amounts (1-3) in all HEP-PG-treated models and in UFH-treated TM2. The mean values 
for each group in TM1 and TM2 were as follows: in TM1 3.2 in the saline group, 2.4 in the 
HEP group, and 2.2 in the HEP-PG group (p=ns); and in TM2 2.8 in the saline group, 2.0 in 
the HEP group, and 2.0 in the HEP-PG group (p=ns). In the anastomosis model, HEP-PG 
significantly inhibited thrombus growth in comparison with saline control (see Figure 5 A).  
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In the 3-day follow-up study of the anastomosis model (experiment III), SEM analysis was 
performed on four samples in each irrigation solution group. All HEP-PG-treated vessels 
remained patent (see Table 14), and according to SEM all these anastomosed surfaces were 
uniformly clean or coated only with a minimal amount of platelets, and thus differed 
noticeably from the other two treatment 
modalities (data not shown).  
 
Figure 5. Results of (A) SEM analysis and 
(B) quantification of the deposited Indium 
111-labelled platelets in the early (10 min) 
anastomosis model. Thrombus scale (in A) 
refers to the semiquantitative extent of 
thrombosis, 1 = clean or minimal amount, 2 
= small amount, 3 = moderate amount, and 
4 = large amount. * p < 0.05, one-way 
ANOVA, repeated measures. 
 
 
Deposition of Indium 111-labeled 
platelets  
 
Early thrombus formation in the anastomoses at 10 min was quantified by using Indium 111-
labelled platelets (experiment II). Consistently, with the above SEM analysis, the Indium 111-
labelled platelets deposited on the anastomosed vessel site in the order: saline group > HEP 
group > HEP-PG group. The HEP-PG group accumulated a significantly smaller amount of 
platelets than did the saline group, whereas there was no difference between the HEP group 
and saline (Figure 5 B). The platelet counts behaved similarily in all irrigation solution 
groups, and were in the different groups pre/postoperatively as follows (mean, range, 106/ml): 
saline group 936/920 (845-1150/799-1004), HEP group 911/880 (864-939/850-916), and 
HEP-PG group 935/873 (891-993/717-966).  
 
 71 
6. DISCUSSION 
 
Local thrombi at microanastomoses threaten the outcome of tissue transplantations (Khouri 
1992). An occlusion formed intraoperatively is easier to detect in time to salvage the 
transplanted tissue, whereas thrombi formed during the postoperative period may be observed 
too late, and part of, or even the whole, flap may develop necrosis. Recent studies have 
described sensitive, new markers for coagulation and fibrinolysis that have been found 
promising in detecting threatening or obvious thrombosis during heterogeneous microsurgical 
reconstructions in various diseases (Komuro et al. 1998).  
 
Our studies show that the problem of thrombosis still exists in microsurgery. Two thirds of 
the TRAM patients had an event of intraoperative local thrombosis, one third of the patients 
with lower extremity trauma required reoperation, and two out of seven cancer patients had 
thrombotic events either during or after surgery. However, only one of the flaps was lost. The 
greater amount of thrombotic events in the TRAM group could be due to the fact that the 
vessels are smaller and often located in scarry tissue whereas those in the two other groups are 
larger, and in the head and neck area the flow is higher (Lorenzetti et al. 2001). 
 
The plasma markers used in this study are very specific and sensitive in measuring the 
activation of thrombin and plasmin. Their capacity to predict or diagnose local thrombosis is, 
however, a different matter. Through careful sample handling special attention was paid to 
preventing artificial activation of blood coagulation and fibrinolysis (Hafner et al. 1993, 
Iversen 1997). Since the ELISA assays used are quantitative, the results may not be applicable 
to semiquantitative latex and haemagglutination tests (Meissner et al. 2000).  
 
Preoperative assessment of hypercoagulability showed that half of the TRAM patients with an 
intraoperative thrombotic event had enhanced thrombin generation, revealed by TAT and/or 
F1+2, before primary surgery. Patients with lower extremity trauma had higher levels of 
fibrinogen, D-dimer and tPA than did TRAM patients, reflecting long-lasting activation of the 
coagulation system (Brozovic 1977, Bennet and Towler 1985). Within the lower extremity 
trauma group, the patients with surgically treated recent trauma had clearly higher D-dimer 
levels than did patients with old trauma. In the cancer group assessment of preoperative 
hypercoagulability with fibrinogen and/or D-dimer revealed that half of the patients were 
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hypercoagulable, a finding that is consistent with reports published elsewhere (Yoda and 
Tsukasa 1981, Falanga et al. 1993, Falanga and Rickles 1999). The same was true when more 
sensitive markers, TAT and F1+2, were used, likewise in conformity with other reports 
(Falanga et al. 1993, Falanga and Rickles 1999, Gouin-Thibault and Samama 1999). 
However, no significant differences were noted in the plasma markers at baseline between 
patients with and patients without intraoperative local thrombosis, except for slightly 
enhanced fibrinolysis, with elevated levels of tPA, in the patients without thrombosis.  
 
The thrombin markers TAT and F1+2 were found to have potential in predicting thrombotic 
risk in the context of both intraoperative thrombosis and reoperation within all groups. In half 
of the TRAM patients with intraoperative thrombosis, the markers of thrombin generation 
increased at the time of obvious thrombosis or reoperation. Of interest was the finding of a 9-
fold increase in TAT on the 1st postoperative day in the patient who went on to develop edge 
necrosis some months later. In the lower extremity trauma group, one third of the patients, all 
with excessive bleeding, showed distinct thrombin generation at the end of primary surgery, 
and later on the same day all underwent reoperation. One of them also generated excessive 
thrombin on the 8th postoperative day upon the removal of a necrotic flap. In the cancer 
group, the patients with thrombotic events, and who were in a clear hypercoagulable state 
before surgery, showed increased thrombin generation at the time of thrombosis, as well. 
  
We also investigated how surgery itself with the associated bleeding would affect the plasma 
markers. An earlier study on coagulation activation during microsurgery showed that, the 
thrombin markers gradually increased during the operation in some of the patients (Komuro et 
al. 1998). In the present study, TAT values increased markedly towards the end of the 
operation in half of the lower extremity trauma patients and in all, but one, of the patients 
with cancer and likewise in all, but one, of the TRAM patients without thrombosis, indicating 
distinct thrombin generation in response to surgical trauma and possibly ischaemia and 
reperfusion (Holmberg et al. 1999). The values returned to normal the next day in all patients 
except for the two with lower extremity trauma who underwent reoperation. Interestingly, this 
phenomenon was not found in the TRAM patients with intraoperative thrombosis, suggesting 
consumption of antithrombin III, a hypothesis that needs to be tested in a further study. A 
general decrease in fibrinogen levels, due to haemodilution and bleeding, followed by an 
increase on the 1st postoperative day, has been reported elsewhere (Brozovic 1977, Bennett 
and Towler 1985, Murray et al. 1988, Fujii et al. 1994, Peltonen et al. 1997).  Increased fibrin 
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turnover has previously been shown in the context of surgery and bleeding as well (Fujii et al. 
1994, Peltonen et al. 1997). In the present study, the cancer patients showed markedly 
elevated D-dimer levels on the 1st postoperative day, as did the TRAM patients, only to a 
lesser extent. Activation of the fibrinolytic system, as measured by tPA and PAI-1 levels, was 
seen only in some of the vascular compromised patients. Also, ischaemia and tourniquet 
application have been found to promote fibrinolysis (Brozovic 1977, Petäjä et al. 1987, Niemi 
et al. 1996), although this was not found in our combined group of patients. The interactive 
complexity of the activation of the coagulation and fibrinolytic systems with the changes in 
haemorheology during surgery is reflected in the vast number of other significant correlations 
between the operative events and plasma markers. 
 
The intraoperative use of unfractionated heparin in six patients was necessitated mainly by 
manifest local thrombosis, and half of these patients required reoperation as well. During 
active inflammation caused by increased concentrations of several acute phase proteins, the 
specifity of heparin binding to antithrombin III diminishes. Even before the operation, the D-
dimer level in the heparinised group was almost 3-fold that in the other patients, which is 
compatible with the finding that pre-existing enhancement of fibrin generation complicates 
the operative outcome. No difference in plasma markers between heparinised and non-
heparinised patients was observed at the end of the operation, suggesting that heparin did 
neutralise some, but only some, of the excessive thrombin generation in the complicated 
cases, since persistent thrombin formation was measured on the 1st postoperative day in the 
group receiving heparin (Amelsberg et al. 1992).  
 
Preoperative anticoagulation therapy with LMWH, dalteparin, was given routinely for 
prophylaxis of deep vein thrombosis and pulmonary embolism (Weitz 1997, Prandoni 2001). 
As recently suggested, the efficacy of LMWH might be improved by monitoring anti-factor 
Xa levels (Hirsh et al. 2001). In our studies, the anti-thrombotic effect of dalteparin turned out 
to be incomplete in the patients who had received it the previous evening, as measured by 
anti-factor Xa levels. This is not surprising since the doses used were low and the half-lives of 
LMWH range from 2 to 4 h for anti-factor Xa activity (Bergqvist et al 19983, Nader et al. 
1999). However, even in some patients who had received dalteparin a few hours before 
surgery, the dose did not cover the whole operation. No significant associations could, 
however, be seen between the timing of LMWH or level of anti-factor Xa and the baseline 
levels of plasma markers or occurrence of thrombosis in this small number of patients.  
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Enhanced anticoagulation therapy is recommended in oncological surgery since cancer 
patients undergoing extensive surgery are considered to be at particularly high risk of 
developing thromboembolic complications (Gouin-Thibault and Samama 1999, Prandoni 
2001). The risk of haemorrhagic complications has, however, discouraged some 
microsurgeons from the systemic use of anticoagulants during extensive reconstructive 
operations. Yet, previous studies have shown that the use of LMWH, even in high dosages, 
does not lead to enhanced bleeding in cancer patients (Bergqvist et al. 1995, Gondret et al. 
1995, Enoxan Study group 1997). In these patients, as well as in those with recent trauma, 
recognition of the procoagulant state could help us to target meticulous antithrombotic 
protection during and after surgery. Further studies will show how enhanced anticoagulation 
therapy influences coagulation activation and perioperative bleeding during microsurgical 
reconstructions.  
 
Since local thrombotic problems were encountered during many of the reconstructive 
procedures, we were also interested in evaluating the failed vessel anastomoses. The novelty 
of these studies was that they focused mainly on arterial anastomoses that failed during 
primary microsurgery; previously, failed human anastomoses have mostly been harvested at 
reoperations (Lidman and Daniel 1981, Gu et al. 1992). As the majority of the anastomoses in 
our study were done by experienced microsurgeons, the technical quality was good - only in 
two cases had a thrombus formed adjacent to a constricting suture. The thrombus size varied 
in the samples from a clear, either occlusive or partial, clot to a mural thrombus with an open 
lumen. In at least one of these samples, during vessel harvesting, a loose red thrombus had 
dropped out at the time of resection. 
 
The immunohistochemichal analysis sought to reveal the three main factors underlying 
thrombus formation: endothelial cell damage, and the accumulation of platelets and of fibrin. 
These markers have not been used previously in this context. Our finding of loss of 
endothelial cells around the anastomoses is consistent with earlier studies, both experimental 
and clinical, and is considered normal (Acland and Tranchtenberg 1977, Lidman and Daniel 
1981). However, the use of clamps or heparinised saline irrigation instead of lactated Ringer’s 
solution may have contributed to this injury (Acland et al. 1980, Thomson et al. 1998). When 
vein graft was used, the endothelium in the middle of the graft was intact and the lumen open, 
as the thrombus had formed adjacent to both anastomoses. We found that the de-
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endothelialised anastomoses were covered with platelets and fibrin. The staining pattern for 
platelets and fibrin correlated, suggesting that the platelet thrombi had proceeded to a stage of 
stabilisation by mature fibrin strands (Bennett and Towler 1985). Earlier, experimental studies 
on anastomotic healing have shown that a monolayer of platelets normally exists at the site of 
endothelial damage (Nightingale et al. 1980, Sigurbjörnsson et al. 1994). Of interest would 
have been to study the amount of platelets and fibrin needed for anastomotic sealing in a well-
functioning anastomosis, but this information was not available for comparison. A novel 
finding was the absence of PECAM-1 staining in the single adherent layers of platelets, 
whereas PECAM-1 was found positive in micro and larger thrombi. As PECAM-1 is 
currently throught to represent an inhibitory signalling molecule involved in platelet adhesion, 
our finding is important and calls for further studies (DeLisser et al. 1993, Newman 1999). 
 
Experimental studies have shown that leukocytes appear at anastomoses from 1 h onwards 
(Nightingale et al. 1980). It has been found that endothelial cells and platelets via their surface 
protein, P-selectin, may localise leukocytes to the region (Ruggeri and Ware 1993, Ware and 
Coller 1995, Downing et al. 1997). The release of vasoactive and mitogenic agents from 
platelets can also contribute to the inflammatory response (Ware and Coller 1995). In our 
study, inflammatory cells had accumulated in one of the samples harvested at the second 
intraoperative thrombotic event. At reoperations, however, all the thrombosed vessels showed 
distinct inflammation, consistent with previous findings (Lidman and Daniel 1981, Gu et al. 
1992). Even the internal elastic lamina were disrupted in some of the inflamed vessels, as 
reported earlier (Lidman and Daniel 1981), indicating proteolytic remodelling in the vessel. 
Also, fibrin associated with these deeper structures of the vessel are indicative of local 
activation of coagulation.  
 
The ideal antithrombotic agent is still lacking (Cooley and Gould 1991). Even at an optimal 
plasma anticoagulation level, the antithrombotic effect of systemic heparin has proved to be 
inadequate to address the mechanisms of arterial thrombosis (Johnson and Barker 1992, 
Maraganore 1993, Arnljots and Bergqvist 1995, Arnljots et al. 1997). Recently, HEP-PG have 
shown promise in blocking thrombus growth, in contrast to standard heparins, in an arterial 
thrombosis model in vitro (Lassila et al. 1997). The inhibitory effect of HEP-PG on platelet-
collagen interaction was observed at both low and high shear rates, the shear-induced 
enhancement of platelet deposition being fully eliminated. The efficacy of soluble HEP-PG 
depended both on the inhibition of GPIa/IIa-mediated platelet recruitment and on tight 
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binding to von Willebrand factor. More recently, similar results have been obtained by 
immobilising HEP-PG together with collagen (Kauhanen et al. 2000). 
 
New antithrombotic agents can be studied in vivo in a multitude of more or less artificial 
models of vascular trauma. In our pilot studies we first used two models in which the 
subendothelial collagen was exposed to circulating platelets to varying extents. The first 
model, that of Davidsson et al., was chosen to create a severe lesion on the endothelium, 
intima and media by scratching the vessel, but was modified by omitting stasis (Davidson et 
al. 1990). In a related model, Rooks et al. have shown that patency was directly related to the 
length of stasis after vessel repair; when no distal clamping occurred, the patency was 100%, 
whereas with 90 s clamping the patency rate fell to 20% (Rooks et al. 1993). We confirmed 
this finding in our experiments - except for some reflow problems all the vessels were patent. 
The overall suitability of this thrombosis model was compromised by the large variability 
caused by the difficulty of standardising the scratching procedure. The second model was 
intended to simulate an injury revealing all layers of the vessel wall including the adventitia, 
especially the most thrombogenic collagen types I and III encountered in the media and 
adventitia (Kehrel 1995). Scanning electron micrographic analysis of this model was not 
feasible, since only the superficial thrombus attached to the flap surface could be observed 
and we could not quantify the extent of thrombotic response underneath the flap. 
Quantification would, however, have been possible with Indium 111-labelled platelets. 
 
The anastomosis model was technically feasible, reproduceable and amenable to 
semiquantification in SEM. Since it is clinically most relevant in microvascular surgery and 
arteriovenous (a-v) shunts, it was chosen for quantitative analysis with Indium 111-labelled 
platelets and long-term follow-up. Thrombogenicity was enhanced by leaving the adventitia at 
vessel ends, thus allowing adventitial collagen and tissue factor to enter the lumen at needle 
holes and eventually between the sutures (Kehrel 1995).  
 
The effect of repeated patency testing in producing emboli and eventually maintaining 
patency was seen in both the acute and the long-term follow-up groups. In the first series of 
acute thrombosis assessments the repeated patency test revealed possible embolisation in 
some of the control vessels and, moreover, SEM analysis showed the largest number of 
platelets on these vessels. In the 3-day follow-up, one vessel in the HEP group had to struggle 
for patency during the first hour, and two anastomoses in the control group became 
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thrombosed during the same time. In both of these vessels a struggle for patency with 
repetitive occlusion and recanalisation occurred during the first hour to first day after the 
operation. As previous studies have shown, thrombosis is not an all-or-none phenomenon but 
a continuous struggle between coagulation and fibrinolytic systems, from the first minutes to 
hours or even days after surgery (Tangelder 1989, Salemark et al. 1995, Weinzweig and 
Gonzalez 1995, Chen et al. 1996, Arnljots et al. 1997).  
 
In the labelling experiment, two strains of rats were used after a red blood cell-rollage had 
formed on the intraluminal surface in BN/R1 rats. An immunological reaction was suspected 
since the Indium 111-labelled platelets were obtained from animals with an unknown blood 
group, and this could be especially undesirable in the HEP-PG group, which had a double 
load of antigens (Indium 111-labelled platelets and HEP-PG itself). However, the amount of 
platelet accumulation per vessel was on the same level in both rat species, and the results of 
the two strains were combined.  
 
Both the semiquantitative SEM analysis and quantification with Indium 111-labelled platelets 
showed that the thrombotic response was lowest in the HEP-PG group, thus markedly 
differing from the control group. As previously stated, the initial monolayer of platelets on 
endothelial defects is essential in vascular repair as it forms a non-thrombogenic pseudo-
intima that is less attractive to additional platelet accumulation (Nightingale et al. 1980, Yo-
dong et al. 1989, Johnson 1990). Consistent with this finding, most of the HEP-PG-treated 
vessels studied by SEM, revealed only a thin seal of platelets on the injured area. 
Unfractionated heparin in a concentration of 100 U/ml, as used in the present study, has 
previously had some local efficacy experimentally, but higher concentrations have led to 
systemic effects and bleeding (Cox et al. 1992). In our experimental study, no increase in 
anastomotic bleeding was noted with HEP-PG, in contrast to the result with recently 
described locally used agent, FFR-rFVIIa (Sørensen et al. 1999). Even in a concentration 100 
times smaller than that of unfractionated heparin HEP-PG were found to be very effective at 
hindering the growth of thrombi and keeping them mural. HEP-PG, by having a strongly 
retaining bond to extracellular matrix, seem to have potential as a locally active 
antithrombotic agent in arterial circulation. However, further studies are needed to establish 
whether HEP-PG can be used to prevent thombotic events in human circulation as well.
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7. CONCLUSIONS 
 
1. In clinical microsurgery, a preoperative hypercoagulable state was found by using markers 
of coagulation activation (TAT, F1+2 and D-dimer) in half of the patients in each of the 
following study groups: TRAM patients with an intraoperative thrombotic event, patients with 
lower extremity trauma and patients with active cancer. The specific markers of thrombin 
generation, TAT and F1+2, also associated with threatening flap failure, and they could 
possibly be used for the perioperative evaluation of patients needing more intense 
antithrombotic therapy in order to avoid reoperations when more rapid analyses become 
available. 
 
2. The effect of systemic anticoagulation with LMWH, dalteparin, as measured by anti-factor 
Xa levels, turned out to be incomplete in all patients who had received it the previous 
evening. Anticoagulation therapy must be enhanced in patients in a preoperative 
hypercoagulable state, especially in those with recent trauma or active cancer. Further studies 
will show the advantages and disadvantages of higher doses of LWMH, where possible 
hemorrhagic complications can be reduced by assessing the systemic bleeding risk 
preoperatively. 
 
3. Immunohistochemical analysis of failed human anastomoses showed a lack of endothelial 
cells with colocalised recruitment of platelets and fibrin. Of interest was the new finding that 
PECAM-1 staining was absent in the single adherent layers of platelets, but that staining was 
positive in micro and larger thrombi. Inflammation was prominent in vessels collected at 
reoperations. Although technical failures were rare, refined microsurgical techniques remain 
essential in order to diminish thrombotic stimuli.  
 
4. The newly applied, locally active antithrombotic agent, macromolecular HEP-PG, was 
effective in hindering thrombus growth in the anastomoses of common femoral arteries in rats 
acutely (10 min) and in the long-term (3 days) as compared with saline, whereas 
unfractionated heparin in a 100-fold higher concentration failed to markedly reduce the 
thrombotic response. This was evidenced by SEM analysis and quantified with Indium 111-
labelled platelets. The feasibility of applying HEP-PG to inhibit thrombosis under high shear 
rate conditions prevailing during microsurgery and at a-v shunts warrants further studies. 
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